Table of Contents

**Section I – General Guidelines............................................................................................................. 3**

G-100 Regulations and Related Privacy Rules Overview............................................................................................. 3 G-101 Emergency Contact Information ...................................................................................................................... 9 G-102 Roles and Responsibilities............................................................................................................................... 12 G-103 Breach and Notification Guidelines ................................................................................................................ 15 G-104 Minimum Necessary Access............................................................................................................................ 24 G-105 Training Requirements ................................................................................................................................... 26

**Section II – Privacy and Disclosure Rights........................................................................................... 27**

P-100 Privacy Note(s)................................................................................................................................................ 27 P-101 Permitted Disclosures .....................................................................................................................................31 P-102 Mandatory Disclosures....................................................................................................................................34 P-103 Disclosure to Personal Representative............................................................................................................38

**Section III – Business Associates....................................................................................................... 41**

B-100 Business Associates Overview ....................................................................................................................... 41

**Section IV – Security Rule ................................................................................................................ 44**

S-100 HIPAA Security Rule Basics ............................................................................................................................. 44 S-101 Administrative Safeguards.............................................................................................................................. 49 S-102 Physical Safeguards......................................................................................................................................... 51 S-103 Technical Safeguards….................................................................................................................................... 55 S-104 Storage, Transport, Transfer and Transmission ............................................................................................. 59

**Section V – Disposal.......................................................................................................................... 61**

D-100 Disposal of Printed PHI ................................................................................................................................... 61 D-101 Disposal of Electronic PHI ............................................................................................................................... 65 D-102 Disposal of Electronic Devices and Media....................................................................................................... 69

**Section VI – Disaster Preparedness and Response............................................................................. 73**

DI-100 Disaster Preparedness and the Community.................................................................................................. 73

**Quick Information Guide 1.0: Civil and Criminal Penalties................................................................. 77 QuickInformationGuide2.0:HIPAAStateSecurity LawsStatutoryReferences........................................79 Quick Information Guide 3.0: HIPAA Definitions ............................................................................... 81 Quick Information Guide 4.0: Privacy Disclosure Guideline Examples ............................................... 84**

Section I – General Guidelines

G-100 Regulations and Related Privacy Rules Overview

Introduction

The Health Insurance Portability and Accountability Act of 1996 (HIPAA), covers both individuals and organizations. Those who must comply with HIPAA are called “***Covered Entities***” or “***Business Associates***”, which are “***Providers***” when the medical office is involved in HIPAA transactions, when they handle, transmit, store, submit claims, or manage Protected Health Information (PHI).

Scope

Magnolia Diagnostics considers patient privacy and the security of Protected Health Information (PHI) a fundamental responsibility of its operations and the practices of its employees. The term “*Patient and Customer*” for the purpose of this policy, is the “individual” for which the HIPAA and PHI rules apply. The Magnolia Diagnostics leadership and workforce members must be committed to respecting patients’ privacy and safeguarding their individually identifiable health information (also known as “protected health information” or “**PHI**”). This includes, but is not limited to:

a. Responding to patients’ requests for access to, or amendment of, their PHI, restrictions on its disclosure, or an accounting of disclosures.

b. Ensuring the confidentiality, integrity, security, and availability of all PHI created, received, maintained or transmitted by or on behalf of the Medical Office.

Policy Framework

**The United States Department of Health and Human Services (HHS)** has established regulatory requirements for the protection of PHI through the following rules:

***The Privacy Rule***, which sets national standards for when protected health information (PHI) may be used and disclosed. ***The Security Rule***, which specifies safeguards that covered entities and their business associates must implement to

protect the confidentiality, integrity, and availability of electronic protected health information.

***The Breach Notification Rule***, which requires covered entities to notify affected individuals, U.S. Department of Health & Human Services (HHS), and in some cases, notification the media of a breach of unsecured PHI, which also requires notifications to affected individuals and the Secretary of the Department of Health and Human Services.

Policy Statement

In furtherance of its commitment, Magnolia Diagnostics has adopted the following Policies and Procedures (collectively, this “**Policy**”) as an integral part of its operations and requires all employees, volunteers, trainees, and agents under Magnolia Diagnostics control to comply with this Policy, as well as any owner or director who administers or delivers Magnolia Diagnostics services (collectively, “**Workforce Members**”).

This Policy is intended to comply with the standards, requirements, and implementation specifications of the Health Insurance Portability and Accountability Act of 1996, and the regulations set forth at 45 CFR Part 160 and Part 164, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, “**HIPAA**”). HIPAA preempts contrary provisions of State law unless such provisions are more stringent than the HIPAA privacy standard.

The Magnolia Diagnostics leadership, workforce members, and business associates (as defined by HIPAA) have an individual and collective responsibility to protect customers’ Protected Health Information (PHI) as a “Covered Entity” defined by the US Department of Health and Human Services (HHS). PHI includes recognizable patient information in printed, electronic, and spoken formats, photo’s, and any combination of PHI which can be used to identify a person or entity that is protected by HIPAA rules. The policies contained within this manual are subject to change and are not intended to be all inclusive of the HIPAA laws and possible interpretations. Contact the Laboratory Director or designee at any time there is a question regarding a policy or HIPAA incident that may need furtherclarification.

Laboratory Director

The Laboratory Director shall have responsibility for all privacy and security matters and for monitoring compliance with this Policy. In addition, the Laboratory Director shall be responsible for modifying existing or developing and implementing new procedures to ensure Magnolia Diagnostics ongoing compliance with HIPAA, and ensuring that all Workforce Members are trained in accordance with this Policy and certifications of such training and attendance are kept with Magnolia Diagnostics records. All questions, complaints, or reports of violations or other matters are to be directed to the Laboratory Director. The Laboratory Director and the role is further described in Policy G-102 “Roles and Responsibilities”.

1. Protected Health Information

1.1 Protected Health Information (PHI) is any type of information that provides a reasonable basis to identify a patient, including, but not limited to, demographic information that relates to the patient’s past, present or future physical or mental health or condition; the provision of health care to the patient; or the past, present, or future payment for the provision of health care to the patient.

1.2 PHI generally includes many common identifiers, such as name, address, birth date, and social security number. PHI can exist in or on a variety of forms. For example, it can be in “hard copy” or “paper” form, such as a written prescription, or in “electronic” form such as the data used to adjudicate or reconcile payments received for claims. *EPHI* is a common reference for PHI in an electronic format.

1.3 PHI does not include information found in employment records that a Covered Entity, such as Magnolia Diagnostics in its capacity as an employer, including worker’s compensation information, education and certain other records subject to, or defined in, the Family Educational Rights and Privacy Act, or health information that neither identifies nor provides a reasonable basis to identify a patient (De-identified Information), or health information that concerns a patient that has been deceased for more than fifty (50) years.

2. Covered Entities

2.1 A “Covered Entity” is an individual, entity, or group plan that (i) provides or pays the cost of medical care (i.e., a health plan), (ii) processes or facilitates the processing of health information received in a nonstandard format into a standard transaction or a standard transaction into a nonstandard format (i.e., a health care clearinghouse), or (iii) a provider of medical or health services, and any other person or organization that furnishes, bills, or is paid for health care in the normal course of business (i.e., a health care provider). Magnolia Diagnostics is a Covered Entity for the intent and purpose of the policies contained within this HIPAA manual.

1. Designated Record Set

3.1 A “Designated Record Set” is a group of records maintained by or for Magnolia Diagnostics that is (i) the medical office and billing records about a patient maintained by or for a covered health care provider; (ii) the enrollment, payment, claims adjudication, and case or medical management record systems maintained by or for a health plan; or (iii) used in whole or in part by or for the Medical Office to make decisions about the patient.

1. Minimum Necessary Standard

4.1 The “Minimum Necessary Standard” means the standard used to characterize the limited extent (i.e., the minimum amount necessary) to which PHI may be used or disclosed to accomplish an authorized purpose.

4.2 The standard does not apply to the following: disclosures to or a request by a health care provider for treatment; disclosures to the patient or the patient’s Personal Representative; disclosures made in accordance with an express authorization; disclosures to HHS for complaint investigation, compliance review, or enforcement; or other uses or disclosures required by law.

4.3 Further information and examples regarding uses and disclosures are given throughout this policy manual.

1. De-Identified Protected Health Information

5.1 Magnolia Diagnostics distinguishes that “De-identified Information” is protected health information from which individually identifiable information has been removed and, when combined with any other information, does not identify the patient.

5.1.1There are only two ways to de-identify health information: (i) a formal determination by a qualified statistician; or (ii) the removal of specified identifiers of the patient and of the patient’s relatives, household members, which will be deemed adequate only if the covered entity has no actual knowledge that the remaining information could be used to identify the patient.

1. Unsecured Protected Health Information

6.1 Unsecured PHI is: PHI that is not rendered unusable, unreadable, or indecipherable to unauthorized persons through the use of technology (e.g., encryption) or methodology specified by the Secretary of the Department of Health and Human Services (“HHS”).

1. Other Protected Patient and Customer Information

7.1 It is important to understand that sensitive personal, financial, and other data which is used or could be used to identify a person or entity may also be protected by other U.S. regulatory agencies. Therefore, it is vitally important, that all Workforce Members and Business Associates treat all patient and customer information and data as private and take the necessary steps to maintain appropriate levels of security in accordance with the law.

7.2 The ***Genetic Information Discrimination Act of 2008 (GINA)*** prohibits genetic information discrimination in employment. Under Title II of GINA, it is illegal to discriminate against employees or applicants because of genetic information.

7.3 The ***Fair Credit Reporting Act* (FCRA)** sets out rules for companies that use data to determine creditworthiness, insurance eligibility, suitability for employment, and to screen tenants.

7.4 The ***Gramm-Leach-Bliley (GLB) Act requires financial institutions to send consumer’s annual privacy notices and allow them to opt out of sharing their information with unaffiliated third parties***. It requires financial institutions to implement reasonable security policies and procedures.

7.5 The ***COPPA Rule requires websites and apps to get parental consent before collecting personal information from kids under 13.*** The Rule was revised in 2013 to strengthen kids’ privacy protections and gives parents greater control over the personal information that websites and online services may collect from children under the age of thirteen.

7.6 The ***Disposal Rule under the Fair and Accurate Credit Transactions Act of 2003 (“FACTA”***), which amended the FCRA, requires that companies dispose of credit reports and information derived from them in a safe and secure manner.

7.7 The ***Red Flags Rule*** requires financial institutions and certain creditors to have identity theft prevention programs to identify, detect, and respond to patterns, practices, or specific activities that could indicate identity theft.

7.8 The ***Telemarking Sales Rule*** requires telemarketers to make specific disclosures of material information; prohibits misrepresentations; limits the hours that telemarketers may call consumers; and sets payment restrictions for the sale of certain goods and services.

References

The ***Health Insurance Portability and Accountability Act of 1996 (HIPAA)*,** Public Law 104-191, was enacted on August 21, 1996. Sections 261 through 264 of HIPAA require the Secretary of HHS to publicize standards for the electronic exchange, privacy and security of health information. Collectively these are known as the *Administrative Simplification* provisions.

The ***Standards for Privacy of Individually Identifiable Health Information*** (“Privacy Rule”) establishes, for the first time, a set of national standards for the protection of certain health information. The U.S. Department of Health and Human Services (“HHS”) issued the Privacy Rule to implement the requirement of the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). The Privacy Rule standards address the use and disclosure of individuals’ health information—called “protected health information” by organizations subject to the Privacy Rule — called “covered entities,” as well as standards for individuals' privacy rights to understand and control how their health information is used. Within HHS, the Office for Civil Rights (“OCR”) has responsibility for implementing and enforcing the Privacy Rule with respect to voluntary compliance activities and civil money penalties.

The ***Security Rule***, like all of the Administrative Simplification rules, applies to health plans, health care clearinghouses, and to any health care provider who transmits health information in electronic form in connection with a transaction for which the Secretary of HHS has adopted standards under HIPAA (the “covered entities”).

The ***Genetic Information Nondiscrimination Act (GINA)*** was signed into law on May 21, 2008. GINA protects individuals against discrimination based on their genetic information in health coverage and in employment. GINA is divided into two sections, or Titles. Title I of GINA prohibits discrimination based on genetic information in health coverage. Title II of GINA prohibits discrimination based on genetic information in employment.

The ***Health Information Technology for Economic and Clinical Health (HITECH) Act*** through notice and comment rulemaking, as required by the Administrative Procedure Act. These provisions include: business associate liability; new limitations on the sale of protected health information, marketing, and fundraising communications; and stronger individual rights to access electronic medical records and restrict the disclosure of certain information. OCR has issued a Notice of Proposed Rulemaking (NPRM) regarding these provisions. Although the effective date (February 17, 2010) for many of these HITECH Act provisions has passed, the NPRM, and the final rule that will follow, provide specific information regarding the expected date of compliance and enforcement of these new requirements.

The U.S. Department of Health and Human Services (HHS) Office for Civil Rights issued a final rule that implemented a number of provisions of the Health Information Technology for Economic and Clinical Health (HITECH) Act, enacted as part of the American Recovery and Reinvestment Act of 2009, also known as ***the Final Omnibus Rule***, to strengthen the privacy and security protections for health information established under the ***Health Insurance Portability and Accountability Act of 1996 (HIPAA)***.

G-101 Emergency Contact Information

Introduction

This Policy and Procedure manual is organized into functional sections that are designed for ease-of-use and practical application guides that are designed to demonstrate the intent of the policies and procedures, according to Federal, State and Local regulations. The government reserves the right to change public policy and laws that supersede or preempt current policies, which may not be immediately available to the medical office, management staff and personnel.

This policy manual may not cover all potential privacy rights and security within the regulations, guidelines, civil and criminal penalties, or possible exclusions that may apply to the medical office environment. In the event that any topic covered in this manual does not clearly define the expected actions and behaviors of the Magnolia Diagnostics management and workforce members, please contact the appropriate Laboratory Director or Government Agency noted in this policy.

Scope

This Policy and Procedures applies to Magnolia Diagnostics and to its’ Business Associates. In the event that the federal, state or local regulations are more restrictive than the Policies and Procedures in this manual, the guidelines that are most restrictive shall apply.

Emergency Contact Numbers

The person utilizing these policies and procedures in emergency situations shall consider the chain-of- command when reporting emergencies; which begins with the immediate supervisor, followed by the Medical Office Manager. In all emergency situations, the person making contact shall have as much information available as possible regarding the nature of the emergency, the types and possible number of records involved, and if possible, the steps taken to mitigate the breach of Protected Health Information.

Health and Human Services (HHS) Contact Information

For direct media inquiries to the HHS: Press Office at (202) 690-6343  
For questions related to Health Information Privacy or Patient Safety, email OCRPrivacy@hhs.gov.  
For non-privacy related inquiries, including comments or questions about OCR's web site, email OCRMail@hhs.gov or write to:

Office for Civil Rights

U.S. Department of Health and Human Services  
200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 Toll-free: (800) 368-1019: TDD toll-free: (800) 537-7697

New England Region - (Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont)

Office for Civil Rights U.S. Department of Health and Human Services Government Center  
J.F. Kennedy Federal Building - Room 1875 Boston, MA 02203  
Customer Response Center: (800) 368-1019 Fax: (202) 619-3818 TDD: (800) 537-7697 Email: ocrmail@hhs.gov

Eastern and Caribbean Region - (New Jersey, New York, Puerto Rico, Virgin Islands)

Office for Civil Rights U.S. Department of Health and Human Services  
Jacob Javits Federal Building 26 Federal Plaza - Suite 3312 New York, NY 10278  
Customer Response Center: (800) 368-1019 Fax: (202) 619-3818 TDD: (800) 537-7697 Email: ocrmail@hhs.gov

Mid-Atlantic Region - (Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia)

Office for Civil Rights U.S. Department of Health and Human Services  
150 S. Independence Mall West, Suite 372, Public Ledger Building Philadelphia, PA 19106-9111  
Customer Response Center: (800) 368-1019 Fax: (202) 619-3818 TDD: (800) 537-7697 Email: ocrmail@hhs.gov

Southeast Region - Atlanta  
(Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee)  
Office for Civil Rights U.S. Department of Health and Human Services  
Sam Nunn Atlanta Federal Center, Suite 16T70 61 Forsyth Street, S.W. Atlanta, GA 30303-8909  
Customer Response Center: (800) 368-1019 Fax: (202) 619-3818 TDD :(800) 537-7697 Email: ocrmail@hhs.gov

Health and Human Services (HHS) Contact Information, Continued

Midwest Region - (Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, Ohio, Wisconsin)

Office for Civil Rights U.S. Department of Health and Human Services  
233 N. Michigan Ave., Suite 240 Chicago, IL 60601  
Customer Response Center: (800) 368-1019; Fax: (202) 619-3818; TDD: (800) 537-7697 Email: ocrmail@hhs.gov

Kansas City

Office for Civil Rights - U.S. Department of Health and Human Services  
601 East 12th Street - Room 353 Kansas City, MO 64106  
Customer Response Center: (800) 368-1019; Fax: (202) 619-3818; TDD: (800) 537-7697 Email: ocrmail@hhs.gov

Southwest Region - (Arkansas, Louisiana, New Mexico, Oklahoma, Texas)

Office for Civil Rights - U.S. Department of Health and Human Services  
1301 Young Street, Suite 1169 Dallas, TX 75202  
Customer Response Center: (800) 368-1019; Fax: (202) 619-3818; TDD: (800) 537 7697 Email: ocrmail@hhs.gov

Rocky Mountain Region - (Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming)

HHS/Office for Civil Rights  
1961 Stout Street Room 08-148 Denver, CO 80294  
Customer Response Center: (800) 368-1019; Fax: (202) 619-3818; TDD: (800) 537-7697 Email: ocrmail@hhs.gov

Pacific Region - (Alaska, American Samoa, Arizona, California, Commonwealth of the Northern Mariana Islands, Federated States of Micronesia, Guam, Hawaii, Idaho, Marshall Islands, Nevada, Oregon, Republic of Palau, Washington)  
Office for Civil Rights U.S. Department of Health and Human Services  
90 7th Street, Suite 4-100 San Francisco, CA 94103  
Customer Response Center: (800) 368-1019; Fax: (202) 619-3818; TDD: (800) 537-7697  
Email: ocrmail@hhs.gov

G-102 Roles and Responsibilities

Purpose

The role of leadership for HIPAA Compliance at Magnolia Diagnostics is defined by the Governing Body of the organization, which may be delegated to location by onsite or offsite representatives, which for the purpose of this policy shall be defined as the Laboratory Director.

The purpose of the Magnolia Diagnostics HIPAA Policy is to provide the structure, policies, and procedures for the security of confidential and protected information throughout the organization. This policy applies to all board members, employees, volunteers, agents, interns, contractors and agents, regardless of whether or not the individual in question works directly with such information. Individuals who have access to confidential information must ensure that such information, in whatever form it exists, is handled in strict accordance with this policy and applicable legal, accreditation and regulatory requirements regarding safeguarding confidential information.

It is the intent of Magnolia Diagnostics that the responsibility for maintaining HIPAA compliance not be totally dependent on leadership, rather than leadership can depend on a fully trained and aware workforce, to identify and close gaps in HIPAA privacy and security that they encounter in their daily responsibilities. It is imperative that ALL members of the Magnolia Diagnostics team, including employees, interns, students, volunteers, and any member that has access or control of PHI to ***SPEAK UP*** to their supervisor or leadership if a potential vulnerability exist that is not being immediately addressed.

The Role of the Laboratory Director

The Laboratory Director ensures continued compliance with all national, state, and local regulations related to medications and their management.

The Laboratory Director will coordinate additional resources as needed, to include legal advice and intervention, outside specialist, and internal resources to address the issues of the breach and make recommendations and additional policies as needed.

The Laboratory Director shall maintain the overall responsibility for the ongoing maintenance, security, access, and updates for all Magnolia Diagnostics information systems. This includes assigning access, data back-up, authentications and digital signatures guidelines and assignments. The Laboratory Director shall conduct or oversee internal and external system audits to include establishment of periodic BA audits or reviews. The results of the audit shall be shared with the appropriate executive for collaboration and coordination of improvement activities and policy development.

The Role of the Laboratory Director, Continued

The Laboratory Director shall maintain emergency management procedures for all systems in the event of a major catastrophe, significant breach, or equipment malfunction, to include temporary measures to ensure that customer/patient care and PHI are not compromised. The Laboratory Director may appoint shift HIPAA Compliance Specialist in their absence. Shift Compliance Specialist must have additional training beyond the basic HIPAA Guidelines to include HIPAA for Managers and Supervisors or an equivalent training course.

Complaints and concerns regarding procedural issues, potential or identified risks, suggestions for improvements, and reports of breach or potential breaches shall be directed to the Laboratory Director which can be reached at (972) 707-9928.

Workforce Members

Workforce Members shall maintain personal responsibility for maintaining PHI security and system integrity at all times and shall report any breaches, attempted breaches, and potential security issues to the Laboratory Director (to include notification to their immediate supervisor). Taking personal responsibility includes taking precautions when handling PHI in any format, not sharing or compromising passwords, not using or transferring PHI to unauthorized electronic devices (laptops, PDA’s, removable storage devices), ensuring that PHI is encrypted if authorized to send electronically, and to limit discussions that may involve PHI in public places, around other Workforce Members that do not have the authorization to listen to potential PHI disclosures, and among family and friends.

Workforce Members must protect their passwords and PHI that could be visible by others, by signing out of devices when unattended. Report any unusual emails or password compromises to your immediate supervisor. All electronic devices used in conjunction with PHI must be approved in advance by the Laboratory Director.

If a Workforce Member knows or should have known of any violation of the HIPAA Policy or any act that would compromise PHI, the Workforce Member is obligated to bring the violation to the attention of your supervisor or the Laboratory Director.

Supervisors are required to report violations to the Laboratory Director and will not disclose the source of the information when legally acceptable for the source to remain confidential. Disclosures that are made by Workforce Members that accidentally violate policy that does not result in a reportable breach of PHI will not be subject to severe disciplinary action, if such violations are found to be accidental, non- malicious, and are disclosed to help improve security of PHI.

Any Workforce Member that knowingly or maliciously violates the HIPAA Policy may be subject to severe disciplinary action, up to and including suspension and termination of employment for the first occurrence. Incidents of this nature will be reviewed by Human Resources and Legal Counsel.

Workforce Members are advised that **intentional release or participation in potential criminal activities** associated with or involved with the release of PHI may also be subject to criminal and/or civil penalties to the maximum allowable by law. The Laboratory Director reports all suspected criminal actives related to HIPAA laws to the local law enforcement agency.

A definition of ***Workforce Member*** can be found in Quick Information Guide 3.0: HIPAA Definitions.

Business Associates

Business Associates are required to sign and adhere to the Magnolia Diagnostics’ Business Associate Agreement in order to provide goods and services as a “Covered Entity” as defined by HIPAA, HITECH and the Final Omnibus Rule. Business Associates must not make assumptions about Workforce Members authorization for access to PHI and must ensure that PHI is not accidentally transmitted or requested from unauthorized sources.

Business Associates must have the appropriate protections and systems in place to prevent, detect, and respond to malware, viruses, and other sources used to breach PHI data. All breaches of PHI must be reported immediately to the Laboratory Director and the manager or supervisor on duty at the medical office or to the **emergency contact number located in Policy G-101 Emergency Contact Information**.

“A Business Associate may use or disclose protected health information only as permitted or required by its Business Associate contract or as required by law. A Business Associate is directly liable under the HIPAA Rules and subject to civil and, in some cases, criminal penalties for making uses and disclosures of protected health information that are not authorized by its contract or required by law. A Business Associate also is directly liable and subject to civil penalties for failing to safeguard electronic protected health information in accordance with the HIPAA Security Rule”.

Violations of the Magnolia Diagnostics’ HIPAA Policy or violations of the HIPAA, HITECH, and Final Omnibus Rules may result in termination of the Business Associates contract for goods and services. Cancellation of Agreements under this provision are not subject to penalties or liquidated damages due to early termination.

A definition of ***Business Associate*** can be found in Quick Information Guide 3.0: HIPAA Definitions.

G-103 Breach and Notification Guidelines

Introduction

The HIPAA Breach Notification Rule, 45 CFR §§ 164.400-414, requires HIPAA covered entities and their business associates to provide notification following a breach of unsecured protected health information. Similar breach notification provisions implemented and enforced by the Federal Trade Commission (FTC), apply to vendors of personal health records and their third-party service providers, pursuant to section 13407 of the HITECH Act. Magnolia Diagnostics is a “Covered Entity” that must abide by the rule, and have a process for communicating to individuals, groups of individuals, the public, media, and the Secretary of HHS.

Scope

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director.

Exceptions to the Breach Notification Rule

**A breach is, generally, an impermissible use or disclosure under the Privacy Rule that compromises the security or privacy of the protected health information.** The Laboratory Director will conduct a review of breaches and disclosure of protected health information to determine if there was an actual and reportable breach or if there is a low probability that the protected health information has been compromised based on a risk assessment of at least the following factors:

The nature and extent of the protected health information involved, including the types of identifiers and the likelihood of re-identification; The unauthorized person who used the protected health information or to whom the disclosure was made; Whether the protected health information was actually acquired or viewed; and the extent to which the risk to the protected health information has been mitigated.

Covered entities and business associates, where applicable, have discretion to provide the required breach notifications following an impermissible use or disclosure without performing a risk assessment to determine the probability that the protected health information has been compromised.

There are ***three exceptions to the definition of “breach.”*** The first exception applies to the unintentional acquisition, access, or use of protected health information by a workforce member or person acting under the authority of a covered entity or business associate, if such acquisition, access, or use was made in good faith and within the scope of authority. The second exception applies to the inadvertent disclosure of protected health information by a person authorized to access protected health information at a covered entity or business associate to another person authorized to access protected health information at the covered entity or business associate, or organized health care arrangement in which the covered entity participates. In both cases, the information cannot be further used or disclosed in a manner not permitted by the Privacy Rule.

The final exception applies if the Covered Entity or Business Associate has a good faith belief that the unauthorized person to whom the impermissible disclosure was made, would not have been able to retain the information.

Covered Entities and Business Associates must only provide the required notifications if the breach involved unsecured protected health information. Unsecured protected health information is protected health information that has not been rendered unusable, unreadable, or indecipherable to unauthorized persons through the use of a technology or methodology specified by the Secretary in guidance.

Examples of Specific Exceptions to the Breach Notification Rule

|  |
| --- |
| 1. **Private Practice Implements Safeguards for Waiting Rooms**  Covered Entity: Private Practice Issue: Safeguards; Impermissible Uses and Disclosures |
| A staff member of a medical practice discussed HIV testing procedures with a patient in the waiting room, there by disclosing PHI to several other individuals. Also, computer screens displaying patient information were easily visible to patients. Among other corrective actions to resolve the specific issues in the case, Office for Civil Rights (OCR) required the provider to develop and implement policies and procedures regarding appropriate administrative and physical safeguards related to the communication of PHI. The practice trained all staff on the newly developed policies and procedures. In addition, OCR required the practice to reposition its computer monitors to prevent patients from viewing information on the screens, and the practice installed computer monitor privacy screens to prevent impermissible disclosures.  2. **Entity Rescinds Improper Charges for Medical Record Copies to Reflect Reasonable, Cost-Based Fees**  Covered Entity: Private Practice Issue: Access |
| A patient alleged that a covered entity failed to provide him access to his medical records. After OCR notified the entity of the allegation, the entity released the complainant’s medical records but also billed him $100.00 for a “records review fee” as well as an administrative fee. The Privacy Rule permits the imposition of a reasonable cost-based fee that includes only the cost of copying and postage and preparing an explanation or summary if agreed to by the individual. To resolve this matter, the covered entity refunded the $100.00 “records review fee.” |
| 3. **Private Practice Revises Process to Provide Access to Records**  Covered Entity: Private Practices Issue: Access |
| A private practice failed to honor an individual's request for a complete copy of her minor son's medical record. OCR's investigation determined that the private practice had relied on state regulations that permit a covered entity to provide a summary of the record. OCR provided technical assistance to the covered entity, explaining that the Privacy Rule permits a covered entity to provide a summary of patient records rather than the full record only if the requesting individual agrees in advance to such a summary or explanation. Among other corrective actions to resolve the specific issues in the case, OCR required the covered entity to revise its policy. In addition, the covered entity forwarded the complainant a complete copy of the medical record. |

|  |
| --- |
| 4. **Private Practice Revises Process to Provide Access to Records Regardless of Payment Source** |
| Covered Entity: Private Practices Issue: Access  At the direction of an insurance company that had requested an independent medical exam of an individual, a private medical practice denied the individual a copy of the medical records. OCR determined that the private practice denied the individual access to records to which she was entitled by the Privacy Rule. Among other corrective actions to resolve the specific issues in the case, OCR required that the private practice revise its policies and procedures regarding access requests to reflect the individual's right of access regardless of payment source.  5. **Private Practice Provides Access to All Records, Regardless of Source**  Covered Entity: Private Practice Issue: Access |
| A private practice denied an individual access to his records on the basis that a portion of the individual's record was created by a physician not associated with the practice. While the amendment provisions of the Privacy Rule permit a covered entity to deny an individual's request for an amendment when the covered entity did not create that the portion of the record subject to the request for amendment, no similar provision limits individuals' rights to access their protected health information. Among other steps to resolve the specific issue in this case, OCR required the private practice to revise its access policy and procedures to affirm that, consistent with the Privacy Rule standards, patients have access to their record regardless of whether another entity created information contained within it.  6. **Physician Revises Faxing Procedures to Safeguard PHI**  Covered Entity: Health Care Provider Issue: Safeguards  A doctor's office disclosed a patient's HIV status when the office mistakenly faxed medical records to the patient's place of employment instead of to the patient's new health care provider. The employee responsible for the disclosure received a written disciplinary warning, and both the employee and the physician apologized to the patient. To resolve this matter, OCR also required the practice to revise the office's fax cover page to underscore a confidential communication for the intended recipient. The office informed all its employees of the incident and counseled staff on proper faxing procedures. |
| 7. **Private Practice Ceases Conditioning of Compliance with the Privacy Rule**  Covered Entity: Private Practice Issue: Conditioning Compliance with the Privacy Rule  A physician practice requested that patients sign an agreement entitled “Consent and Mutual Agreement to Maintain Privacy.” The agreement prohibited the patient from directly or indirectly publishing or airing commentary about the physician, his expertise, and/or treatment in exchange for the physician’s compliance with the Privacy Rule. A patient’s rights under the Privacy Rule are not contingent on the patient’s agreement with a covered entity. A covered entity’s obligation to comply with all requirements of the Privacy Rule cannot be conditioned on the patient’s silence. OCR required the covered entity to cease using the patient agreement that conditioned the entity’s compliance with the Privacy Rule. Additionally, OCR required the covered entity to revise its Notice of Privacy Practices. |

Breach Notification Requirements

Following a breach of unsecured protected health information, covered entities must provide notification of the breach to affected individuals, the Secretary, and, in certain circumstances, to the media. In addition, business associates must notify covered entities if a breach occurs at or by the business associate.

Individual Notice

I. Covered entities must notify affected individuals following the discovery of a breach of unsecured protected health information. **Covered entities must provide this individual notice in written form by first-class mail, or alternatively, by e-mail if the affected individual has agreed to receive such notices electronically. If the covered entity has insufficient or out-of- date contact information for 10 or more individuals**, the covered entity must provide substitute individual notice by either posting the notice on the home page of its web site for at least 90 days or by providing the notice in major print or broadcast media where the affected individuals likely reside. The covered entity must include a toll- free phone number that remains active for at least 90 days where individuals can learn if their information was involved in the breach. If the covered entity has insufficient or out-of-date contact information for fewer than 10 individuals, the covered entity may provide substitute notice by an alternative form of written notice, by telephone, or other means.

II. These **individual notifications must be provided without unreasonable delay and in no case later than 60 days following the discovery of a breach** and must include, to the extent possible, a brief description of the breach, a description of the types of information that were involved in the breach, the steps affected individuals should take to protect themselves from potential harm, a brief description of what the covered entity is doing to investigate the breach, mitigate the harm, and prevent further breaches, as well as contact information for the covered entity (or business associate, as applicable).

III. A breach at or by a business associate, while the covered entity is ultimately responsible for ensuring individuals are notified, the covered entity may delegate the responsibility of providing individual notices to the business associate. Covered entities and business associates should consider which entity is in the best position to provide notice to the individual, which may depend on various circumstances, such as the functions the business associate performs on behalf of the covered entity and which entity has the relationship with the individual.

Breach Notification Requirements, Continued

Media Notice

Covered entities that experience **a breach affecting more than 500 residents of a State or jurisdiction** are, in addition to notifying the affected individuals, required to provide notice to prominent media outlets serving the State or jurisdiction. Covered entities will likely provide this notification in the form of a press release to appropriate media outlets serving the affected area. Like individual notice, this media notification must be provided without unreasonable delay and in no case later than 60 days following the discovery of a breach and must include the same information required for the individual notice.

Notice to the Secretary

In addition to notifying affected individuals and the media (where appropriate), covered entities must notify the Secretary of breaches of unsecured protected health information. Covered entities will notify the Secretary by visiting the HHS web site:

(http://www.hhs.gov/ocr/privacy/hipaa/administrative/breachnotificationrule/brinstruction.html).

The website is used to electronically submit a breach report form. **If a breach affects 500 or more individuals, covered entities must notify the Secretary without unreasonable delay and in no case later than 60 days** following a breach. If, however, a breach affects fewer than 500 individuals, the covered entity may notify the Secretary of such breaches on an annual basis. Reports of **breaches affecting fewer than 500 individuals are due to the Secretary no later than 60 days after the end of the calendar year in which the breaches are discovered**.

Notification by a Business Associate

If a breach of unsecured protected health information occurs at or by a business associate, the business associate must notify the covered entity following the discovery of the breach. A business associate must provide notice to the covered entity without unreasonable delay and no later than 60 days from the discovery of the breach. To the extent possible, the business associate should provide the covered entity with the identification of each individual affected by the breach as well as any other available information required to be provided by the covered entity in its notification to affected individuals.

Responding to Possible Breaches

Given the potential consequences, it is critical that covered entities and business associates respond appropriately to potential HIPAA breaches to avoid or minimize their liability. Below are steps that you may follow to help identify and timely respond to HIPAA breaches.

1. **Stop the breach.** Immediate action may help avoid or mitigate the effects of a breach. Terminate improper access to PHI; retrieve any PHI that was improperly disclosed; and obtain assurances from recipients that they have not used or disclosed the PHI, and/or will not, further use or disclose PHI that was improperly accessed. Document your actions and the recipient’s response.

2. **Contact the privacy officer.** Each covered entity must have a designated privacy officer who (hopefully) has the training and experience to properly investigate and respond to a potential breach. Deadlines for

responding to breaches generally run from the date that anyone in the organization knew of the breach except the person committing the breach (*see* 45 CFR 164.404(b); 78 FR 5647); accordingly, workforce members should be trained to notify the privacy officer as soon as they become aware of a breach so that appropriate steps can be taken to investigate, mitigate, and respond to any potential breach.

3. **Respond promptly.** Swift, appropriate action is critical for at least four reasons. First, covered entities have an affirmative obligation to mitigate the effects of any breach. (45 CFR 164.530(f)). Second, prompt action may help avoid or mitigate further breaches, which is an important factor in determining whether a breach must be reported. (45 CFR 164.402). Third, as discussed above, a covered entity or business associate may avoid penalties if they correct a violation within 30 days. (45 CFR 160.410(b)). And fourth, the breach notification rule requires that notice of reportable breaches be given “without unreasonable delay,” but no later than 60 days after discovery. (45 CFR 164.404).

4. **Investigate appropriately.** Confirm the “who, what, when, why, how, and how much” with persons involved, including persons who committed the alleged violation; persons who may have received PHI improperly; and other relevant witnesses. Confirm the nature and amount of the PHI that was accessed, used, or disclosed, and why they accessed or disclosed the PHI. Ensure there was no redisclosure and that there will be no further redisclosure. In your discussions, ensure that you do not inadvertently disclose additional PHI. Also, beware acting too swiftly: sometimes a full investigation reveals additional facts that confirm no reportable breach occurred. Do not report a suspected breach before you have actually concluded that a reportable breach occurred. Document your investigation, including obtaining witness statements and sending confirming letters as appropriate. For example, you may want to send a letter to alleged recipients confirming the extent of their access or disclosure of PHI, and warning them of the penalties that may apply if they further use or disclose PHI improperly. (*See* 42 USC 1320d-6).

5. **Mitigate the effects of the breach.** HIPAA requires that a covered entity mitigate any harmful effects of a breach to the extent practicable. (45 CFR 164.530(f)). Mitigation may include retrieving, deleting, or destroying improperly disclosed PHI; terminating access or changing passwords; remote wiping mobile devices; modifying policies or practices; warning recipients of potential penalties for further violations; *etc.* In some cases, it might include paying for the cost of a credit monitoring service or similar action, and/or notifying affected individuals even if the breach is not required to be reported under the breach notification rules. The response will depend on the circumstances. If a covered entity knows that a business associate is violating HIPAA, it must either take steps to cure the breach or terminate the business associate agreement. (45 CFR 164.504(e)(1)).

6. **Correct the breach.** Remember: a covered entity may avoid HIPAA penalties if it did not act with willful neglect and corrects the problem within 30 days. (45 CFR 160.410(b)). Although you may not be able to “unring” the bell, you can ensure that the bell does not continue ringing by, *e.g.*, changing processes; implementing new safeguards; modifying policies; training employees; *etc.* (*See* 75 FR 40879).

7. **Impose sanctions.** HIPAA requires that covered entities impose and document appropriate sanctions against workforce members who violate HIPAA or privacy policies. (45 CFR 164.530(e)). The sanction should fit the crime: it may range from a written warning and additional training to suspension or termination.

8. **Determine if the breach must be reported to the individual and HHS.** Under the breach notification rule, covered entities are only required to self-report if there is a “breach” of “unsecured” PHI. (45 CFR 164.400 *et seq.*).

1. **Unsecured PHI.** “Unsecured” PHI is that which is “not rendered unusable, unreadable, or indecipherable to unauthorized persons through the use of a technology or methodology” specified in HHS guidance. (45 CFR 164.402). Currently, there are only two ways to “secure” PHI: (1) in the case of electronic PHI, by encryption that satisfies HHS standards; or (2) in the case of e-PHI or PHI maintained in hard copy form, by its complete destruction. (74 FR 42742). Breaches of “secured” PHI need not be reported. Most potential breaches will involve “unsecured” PHI.
2. **Breach.** The unauthorized “acquisition, access, use, or disclosure” of unsecured PHI in violation of the HIPAA privacy rule is presumed to be a reportable breach unless the covered entity or business associate determines that there is a low probability that the data has been compromised or the action fits within an exception. (45 CFR 164.402; *see* 78 FR 5641). Thus, the covered entity or business associate must determine the following:
   1. **Was there a violation of the privacy rule?** Breach notification is required only if the acquisition, access, use or disclosure results from a privacy rule violation; no notification is required if the use or disclosure is permitted by the privacy rules. (45 CFR 164l.402). For example, a covered entity may generally use or disclose PHI for purposes of treatment, payment, or healthcare operations without the individual’s authorization unless the covered entity has agreed otherwise. (45 CFR 164.506). Disclosures to family members and others involved in the individual’s care or payment for their care is generally permitted if the patient has not objected and the provider otherwise determines that disclosure is in the patient’s best interest. (45 CFR 164.510). HIPAA allows certain other disclosures that are required by law or made for specified public safety or government functions. (45 CFR 164.512). Disclosures that are incidental to permissible uses or disclosures do not violate the privacy rule if the covered entity employed reasonable safeguards. (45 CFR §§ 164.402 and .502(a)(1)(iii)). When in doubt as to whether a disclosure violates the privacy rule, you should check with your privacy officer or a qualified attorney.
   2. **Does the violation fit within breach exception?** The following do *not* constitute reportable “breaches” as defined by the HIPAA privacy rule:
      * 1. an unintentional acquisition, access, or use of PHI by a workforce member if such acquisition, access, or use was made in good faith and within the scope of the workforce member's authority and does not result in further use or disclosure not permitted by the privacy rules. (45 CFR 164.402). For example, no breach notification is required where an employee mistakenly looks at the wrong patient's PHI but does not further use or disclose the PHI. (74 FR 42747).
        2. An inadvertent disclosure by a person who is authorized to access PHI to another authorized person at the same covered entity or business associate, and the PHI is not further used or disclosed in a manner not permitted by the privacy rules. (45 CFR 164.402). For example, no breach notification is required if a medical staff member mistakenly discloses PHI to the wrong nurse at a facility but the nurse does not further use or disclose the PHI improperly. (74 FR 42747-48).
        3. A disclosure in which the person making the disclosure has a good faith belief that the unauthorized recipient would not reasonably be able to retain the PHI. (45 CFR 164.402). For example, no notification is required if a nurse mistakenly hands PHI to the wrong patient but immediately retrieves the information before the recipient has a chance to read it. (74 FR 42748).

**3. Is there a “low probability that the data has been compromised?”** No breach report is required if “there is a low probability that the [PHI] has been compromised based on a risk assessment” of at least the following factors listed in 45 CFR 164.402:

**1. The nature and extent of the PHI involved** , including the type of information, identifiers and the likelihood of identification. For example, PHI involving financial data (*e.g.*, credit card numbers, social security numbers, account numbers, *etc.*), sensitive medical information (*e.g.*, mental health, sexually transmitted diseases, substance abuse, *etc.*), or detailed clinical information (*e.g.*, names and addresses, treatment plan, diagnosis, medication, medical history, test results, *etc.*) create a higher probability that data has been compromised and must be reported. (78 FR 5642-43). Conversely, merely disclosing the patient’s name without disclosing their health condition may not be reportable.

* + 1. **The unauthorized person who impermissibly used the PHI or to whom disclosure was made.** For example, disclosure to another health care provider or a person within the entity's organization would presumably involve a low probability that the data is compromised because such persons are more likely to comply with their confidentiality obligations and are unlikely to misuse or further disclose the PHI. Similarly, there is a lower risk of compromise if the entity who receives the PHI lacks the ability to identify entities from the limited information disclosed. (78 FR 5643).
    2. **Whether the PHI was actually acquired or viewed.** For example, there is likely a low risk if a misdirected letter is returned unopened or a lost computer is recovered, and it is confirmed that PHI was not accessed. Conversely, there is a higher risk where the recipient opens and reads a misdirected letter even though she reports the letter to the covered entity. (78 FR 5643).
    3. **Whether the risk to the PHI has been mitigated.** For example, there may be a lower risk if a fax is directed to the wrong number, but the recipient confirms that they returned or destroyed the PHI; the PHI was not accessed, used or disclosed, and will not be further used or disclosed; and the recipient is reliable. (78 FR 5643). This factor highlights the need for covered entities and business associates to immediately identify and respond to potential breaches to reduce the probability that PHI is compromised and the necessity of breach reporting.

The risk assessment should involve consideration of all of these factors in addition to others that may be relevant. One factor is not necessarily determinative, and some factors may offset or outweigh others, depending on the circumstances. (*See* 78 FR 5643). If you conclude that the risk assessment demonstrates a low probability that the PHI has been compromised, you should document your analysis and you may forego breach notification. On the other hand, if the risk assessment fails to demonstrate a low probability that the PHI has been compromised, you are required to report the breach to the affected individual and HHS as described below.

The Magnolia Diagnostics Laboratory Director must be informed of all Business Associate Breach Notifications

G-104 Minimum Necessary Access

Introduction

The HIPAA Privacy Rule requires a Magnolia Diagnostics’ (covered entity) to make reasonable efforts to limit use, disclosure of, and requests for protected health information to the minimum necessary to accomplish the intended purpose. The standard requires an approach consistent with the best practices and guidelines already used by many providers and plans today to **limit the unnecessary sharing of medical information**.

The minimum necessary standard requires the medical office (covered entity) to evaluate its’ practices and enhance protections as needed to limit unnecessary or inappropriate access to protected health information. The Privacy Rule allows for professional judgment to appropriately limit access to PHI sacrificing the quality of health care services.

In the Magnolia Diagnostics’ environment, Workforce Members must only access PHI that is necessary to complete job tasks for which they are properly trained and authorized to access. In the event that PHI is observable by a Workforce Member that does not have authorization to view, possess, transport, or transfer PHI, the Workforce Member is required to notify their immediate supervisor or Laboratory Director to appropriately remove unauthorized access or possession. It should be noted that identifying HIPAA Breach risk by non- authorized personnel is encouraged to create an environment of safety and security for PHI in the public and behind-the-scenes environment.

Scope

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics’. In the event it is not clear if this policy applies to you, please contact the Laboratory Director. All Workforce Members are responsible for maintaining the confidentiality and security of Protected Health Information (PHI).

1. Minimum Necessary Access to Protected Health Information (PHI)

1.1.  Only Magnolia Diagnostics ’workforce Members designated as authorized by the Laboratory Director or designee are allowed to access the information defined in the designated record set without prior patient written authorization or unless the purpose falls within the scope of allowable disclosures under HIPAA (i.e. treatment) which includes the information needed to ask medically related questions, provide healthcare services, handle associated paperwork, and interact with patient or customer for all types of interactions that involve PHI.

1.2.  All Magnolia Diagnostics’ patient information is considered confidential and only the information needed for the intended purpose should be used by, and disclosed to covered Workforce Members who have a “need to know” (i.e. Minimum Necessary).

1.3. A Magnolia Diagnostics’ Workforce Member with a “need to know” is defined as someone Section I – General Guidelines | 24 who needs the information because the information is directly related to the duties and activities the person is required to perform as described in their job description. Without such information the staff member would not be able to carry out these functions.

1.4.  Magnolia Diagnostics’ Workforce Members who are patients of the Magnolia Diagnostics’ or who have dependents, family members, co-workers, or friends who are patients of the Magnolia Diagnostics’ must follow standard procedures, applicable to all patients, for accessing their own patient information or the patient information of their dependents, family members, co- workers, or friends.

1.5.  Patient records should be requested through the responsible designee on duty, who shall notify the Laboratory Director. If the request is made by someone other than the patient, either a HIPAA authorization or a power of attorney indicating that the employee is the patient’s representative would need to be present in the file or submitted prior to the release of PHI.

1.6.  Staff members may not discuss PHI with their friends, family members, spouses, or any other individual unless allowable by HIPAA (i.e. have knowledge that an individual is participating in healthcare decisions or payment for healthcare for the patient or a power of attorney indicating that the employee is the patient’s representative.).

1.7.  PHI is protected by law. Inappropriate use or disclosure of Magnolia Diagnostics’ individually identifiable health information will be reported to the Magnolia Diagnostics’ Laboratory Director or designee.

1.8.  Violations of the “Minimum Necessary Access” rules, whereby an exception does not exist or is not appropriate for the reported use may be subject the Workforce Member to disciplinary action, up to and including termination of employment.

1.9.  Intentional violations of the “Minimum Necessary Access” policy that involves criminal activity will be reported to law enforcement agencies and prosecuted to the fullest extent of the law.

G-105 Training Requirements

Introduction

The **HIPAA Security Awareness and Training** §164.308(a)(5) requires Magnolia Diagnostics to provide Security Awareness Training. The **HIPAA Privacy Rule** requires Magnolia Diagnostics to train workforce members to ensure an understanding of privacy procedures. HIPAA Security Awareness Training must include information regarding a minimum of four specifications; Security Reminders, Protection from Malicious Software, Log-in Monitoring, and Password Management. These topics can be combined into a single training course, providing that the subject matter is appropriate for the level of access to PHI by the workforce member receiving the training.

Scope

This policy covers all Workforce Members and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. Business Associates must have similar training requirements that are subject to audit by Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director.

Training Guidelines

1. New workforce members shall be provided training within their first 10 days of employment, unless they can verify equivalent training that they have been deemed competent within the past twelve months in writing or by certificate of completion.
2. Retraining shall be given whenever environmental or operational changes affect the security of PHI, which may include new or updated policies and procedures; new or upgraded software or hardware; new security technology; or changes in the Privacy, Security and Breach Notification Rule.
3. A review of HIPAA guidelines, additional information such as courses for managers and supervisors, the impact of social media and other HIPAA topics are appropriate to meet annual training requirements.
4. All training shall be documented and kept in the employee file for a period of no less than seven (7) years.
5. Retraining of workforce members who violate HIPAA policies, including, unintentional violations or breaches are subject to retraining after an incident or whenever the supervisor or Laboratory Director deems it necessary.

Section II – Privacy and Disclosure Rights

P-100 Privacy Note(s)

Introduction

The HIPAA Privacy Rule gives patient or their representative’s a fundamental new right to be informed of the privacy practices of their health plans and of most of their health care providers, as well as to be informed of their privacy rights with respect to their personal health information. Medical Offices are required to develop and distribute a notice that provides a clear explanation of these rights and practices. The notice is intended to focus patient or their representatives on privacy issues and concerns, and to prompt them to have discussions with their health plans, health care providers, and the organization contact information at each location, with the information needed to exercise their rights.

Scope

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director.

The Privacy Rule and Notification Rule

The Magnolia Diagnostics is covered by the medical information privacy provisions of the Health Insurance Portability and Accountability Act (HIPAA). The organization must comply with HIPAA and the Regulations in the use and disclosure health information by which patients and caregivers can be individually identified, also known as Protected Health Information (PHI). The organization at each location is required under Section 164.520 to provide patients this notice (in paper or electronic format) of the privacy practices concerning their PHI.

1. NoticeAvailability

1.1  The location must post the “Privacy Notice” in a ***clear and prominent location*** where a patient or their representative requests healthcare services, check-in desk, or waiting area.

1.2  The location must make its notice available to any person who asks for it, whether or not they are seeking services being offered by the organization at each location as a “Covered Entity”.

1.3  The location must prominently post and make available its notice on its web site (or corporate website) and provide a method to receive a paper copy of the Privacy Notice.

1.4  The location may e-mail the notice to a patient or their representative, if the individual agrees to receive an electronic notice; however, a paper copy shall always be made available.

1.5  The location may provide the Notice by email if the individual agrees to receiving electronic Notice. If the email transmission has failed, each location must provide a paper copy.

1.6  If the first delivery of the Notice to an individual is electronic the location must provide electronic “Notice” automatically and contemporaneously in response to the individual's first request for service.

1.7  In an emergency, the location will provide the Notice as soon as is reasonably available after the emergency situation has subsided and, relief efforts if required, have restored the location’s operations to normal operating conditions.

2. Privacy Notice Requirements

2.1  Magnolia Diagnostics will provide a Notice that is written in plain language on how each location may use and disclose Protected Health Information (PHI).

2.2  The Notice must contain this statement as a header: “***THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW IT CAREFULLY***.”

2.3  The patient rights with respect to the information and how the individual may exercise these rights, including how the individual may ask questions regarding the Privacy Notice or file complaints on each location’s use of the patients’ (PHI).

2.4  The covered entity’s legal duties with respect to the information, including a statement that the covered entity is required by law to maintain the privacy of protected health information.

2.5  A description and at least one example of the types of uses and disclosures that the organization at the location is permitted to make for treatment, payment, and health care operations.

2.6  A description of each of the other purposes at each location is permitted or required to use or disclose PHI without the individual's written consent.

2.7  If a use or disclosure is prohibited or materially limited by other laws, the description of such use/disclosure must be reflected in the notice.

2.8  The description and examples must include sufficient detail to put the individual on notice of the uses and disclosures that are permitted or required by the privacy regulations and other applicable laws.

2.9  A statement that other uses and disclosures may be made only with the patient or their representative’s written authorization and that the individual may revoke such authorization.

2.10  A statement that the organization is required by law to maintain the privacy of PHI and to provide patient or their representatives with notice of its legal duties and privacy practices.

2.11  A statement that the organization is required to abide by the terms of the Notice currently in effect.

2.12  A statement that the organization reserves the right to change the terms of its Notice and to make the new Notice provisions effective.

2.13  A statement that describes how the organization will provide patents and their representatives with a revised Notice.

2.14  The Notice will contain a statement that individuals may complain to the organization at the location and to the Secretary of the Department of Health and Human Services if they believe their privacy rights have been violated. This statement will include how the individual may file a complaint with the organization and that the individual will not be retaliated against for filing a complaint.

2.15  The Notice must contain the name or title and telephone number of a person or office to contact for further information.

2.16  The Notice must include the date with which the Notice is first in effect, which may not be earlier than the date on which the Notice is printed or otherwise published.

2.17  The organization will state in the Notice that it reserves the right to revise or change its policies and procedures and that the revision may or may not affect all PHI, including previously obtained PHI that the organization at the location it maintains.

2.18  When there is a change in law that necessitates a revision to the organization’s policies and procedures, each location must promptly document and implement the change to include making revisions to the Notice to reflect the change in law.

2.19  The organization may change its policy at any time; however, implementation cannot begin until the notice has been revised and posted. The date of implementation will be on or after the effective date stated in the Notice.

2.20  The organization at the location is required to promptly revise and distribute its notice whenever it makes material changes to any of its privacy practices, and the notice must include an effective date.

1. Notice Requiring Separate Statements

3.1  The Notice must include separate statements if the location plans to engage in any of the following:

3.2  The organization at the location may contact the individual to provide appointment reminders or information about treatment alternatives or other health related benefits or services that may be of interest to the individual.

3.3  The organization at the location may contact the individual to raise funds for the organization.

1. Notice of Individual Rights

4.1  The Notice must contain a statement of the individual's rights with respect to PHI and a brief description of how the individual may exercise these rights.

4.2  The right to request restrictions on certain uses and disclosures of PHI, including a statement that the organization at the location is not required to agree to a requested restriction.

4.3  The right to receive confidential communication of PHI.

4.4  The right to inspect and copy PHI.

4.5  The right to request an amendment to PHI.

4.6  The right to receive an accounting of disclosures of PHI.

4.7  The right to receive a paper copy of the Notice.

1. Notice Revisions

5.1  The organization at the location will retain copies of the Notice (original and revisions), written acknowledgements of receipt, and documentation of good faith efforts.

5.2  The organization at the location will retain documentation for six (6) years from the last date in effect.

References

Title 45 C.F.R. §164.520

P-101 Permitted Disclosures

Introduction

Magnolia Diagnostics is required to maintain the privacy of Protected Health Information (PHI) and to provide patients and their representatives how their PHI may be used and disclosed. The uses and disclosures of PHI by the medical office may include identifying information about past, present and future physical and mental health or conditions, and the provision of healthcare goods and services or payments for these goods and services. There are uses and disclosures that require prior authorization from the patient, caregivers, or a patient’s representative, as well as uses and disclosures that do not require prior authorization.

The uses and disclosures are subject to change and will be made available in electronic and paper format, at the medical office where services are rendered, on the official website or upon request. The uses and disclosures of PHI shall be maintained in the Magnolia Diagnostics official Privacy Notice as required under HIPAA laws and regulations.

Some types of PHI, such as HIV information, genetic information, alcohol and/or substance abuse records, and mental health records may be subject to special confidentiality protections under applicable state or federal law and Magnolia Diagnostics will abide by all applicable protections. Additional information will be made available by contacting the Laboratory Director for location specific questions and information.

Scope

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director or designee.

1. The Privacy Rule and Notification Rule Consent and Authorization

1.1.  Magnolia Diagnostics is covered by the medical information privacy provisions of the Health Insurance Portability and Accountability Act (HIPAA).

1.2.  The Privacy Rule permits, but does not require, the Magnolia Diagnostics to voluntarily to obtain patient consent for uses and disclosures of protected health information for treatment, payment, and health care operations.

1.3.  WherethePrivacyRulerequirespatientauthorization,voluntaryconsentisnotsufficienttopermitause or disclosure of protected health information unless it also satisfies the requirements of a valid authorization. An authorization is a detailed document that gives covered entities permission to use protected health information for specified purposes, which are generally other than treatment, payment, or health care operations, or to disclose protected health information to a third party specified by the individual.

1.4 In situations where the Privacy Rule requires patient authorization, voluntary consent is not sufficient to permit a use or disclosure of PHI unless it also satisfies the requirements of a valid authorization. An authorization must provide recorded in a detailed document that gives the Magnolia Diagnostics permission to use protected health information for specified purposes, which are generally other than treatment, payment, or health care operations, or to disclose protected health information to a third party specified by theindividual.

2. Permitted Uses and Disclosures of Protected Health Information (PHI)

2.1  The Magnolia Diagnostics can use PHI for the treatment, payment, or health care operations, as permitted by and in compliance with § 164.506. The term of “uses” and “disclosures” within the context of this section are interchangeable and are defined as “disclosures”.

2.2  Magnolia Diagnostics may disclose PHI related to a patient’s treatment which may include the provision, coordination, or management of health care and related services (including coordination and management by a provider with a third party; consultation between health care providers relating to a patient; or referral of patient for health care from one provider to another). In the Medical Office setting this may include a discussion regarding a patient with a provider or a clinician for consultations prevention of medication reactions, and patient medication and health history.

2.3  Magnolia Diagnostics may disclose PHI to secure payment or provide information to health plans associated with a patient’s benefits. This includes, but is not limited to, activities related to coverage and eligibility determinations, billings, claims management, collections, review of services related to medical necessity or justification for charges, UR activities, and certain disclosures (e.g., name, address, DOB, account number) to consumer reporting agencies.

2.4  Magnolia Diagnostics may disclose PHI in the course of business operations. Operations is defined as necessary activities to conduct quality assessments and improvement activities including contacting patients and health care providers with information about treatment alternatives. Magnolia Diagnostics may use and disclose medical information to assess the use or effectiveness of certain medications, development and monitoring of medical protocols, and to provide medication reminders within the permissible limits of the Privacy Rule.

2.5 Privacy principles does not prohibit incidental disclosure of patient information so long as reasonable safeguards are taken to minimize the disclosure. Reasonable safeguards include:

2.5.1  Avoiding conversations that include PHI in front of other patients/customers.

2.5.2  Lowering voices when discussing patient/customer’s information in person over the phone.

2.5.3  Avoiding conversations about patients/customers in public places, such as outside of the medical office area, front desk, and walkways.

2.6  Conversations discussing PHI should be conducted in a private area or room, especially when discussions involve **highly confidential information** (i.e. Mental Illness or Developmental Disability, HIV/AIDS Testing or Treatment, Communicable Diseases, Venereal Disease(s), Substance (i.e. alcohol, drugs) Abuse, Abuse of an Adult with a Disability, Sexual Assault, Child Abuse and Neglect, Genetic Testing, Artificial Insemination, and Domestic Violence).

2.7  If a workforce member over hears other workforce members or Business Associates discussing PHI inappropriately, it is acceptable to request that person “Breaching HIPAA Rules” abide by the Privacy Rule or report it to their immediate supervisor.

P-102 Mandatory Disclosures

Introduction

A major purpose of the Privacy Rule is to define and limit the circumstances in which an individual’s protected heath information may be used or disclosed by covered entities. A Covered Entity may not use or disclose protected health information, except either: (1) as the Privacy Rule permits or requires; or (2) as the individual who is the subject of the information (or the individual’s personal representative) authorizes in writing.

Magnolia Diagnostics is a Covered Entity, and must disclose Protected Health Information (PHI) in two situations: (a) to individuals (or their personal representatives) specifically when they request access to, or an accounting of disclosures of, their protected health information; and (b) to the US Department of Health and Human Services (HHS) official for the purpose of an investigation, review, or enforcement action.

There are certain situations that involve other organizations, such as the military, law enforcement, the judicial system and others, where disclosure of PHI is required due to an investigation or other permitted use under the Privacy Rule that takes precedents over an individual’s right to privacy under HIPAA.

When a workforce member is requested PHI due to a mandatory disclosure requirement under HIPAA, it does not prevent the workforce member from requiring certain information and verification that the “authority” requesting access to PHI. In the event that a workforce member receives a request for a mandatory request of PHI, they must notify their immediate supervisor or the Laboratory Director.

Scope

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director.

1. Mandatory Disclosures

1.1.  In the event of a request for an official Mandatory Disclosure of Protected Health Information(PHI) the following procedures must be followed.

1.2.  The work force member is to tell the requestor that the workforce member is required to notify the Magnolia Diagnostics Laboratory Director and will need to go through a brief process prior to release of requested records.

1.3.  In the event that the request is made in person, the workforce member is to immediately notify the Laboratory Director.

1.4  In the event that the Laboratory Director is not immediately available, the workforce member will notify and engage the on-duty manager or supervisor. The manager or supervisor must step in and take over the conversation with the requestor.

1.5  The on-duty manager or supervisor will politely ask the requestor to wait momentarily while the on- duty manager or supervisor notifies the Laboratory Director.

1.6  If the Laboratory Director is not available, a designee, manager or supervisor may comply with the request, providing the designee, manager or supervisor has been specifically trained on this policy and collects all the pertinent identification from the requestor and a signed release form.

1.7  If the requestor appears in person, verify that the person is an “Official” that is listed in this policy.

1.8  Using the Mandatory Disclosure Form (located in Appendix C – HIPAA Forms. Make certain to gather all required information, including, name, badge number or other agency identification, credentials or proof of government status.

1.9  Request to make a photo copy of the “Official Request” and the identification of the requestor, by taking a photocopy of their identification and writing down their name and identification number on the printed copy, sign and date the copy.

1.10  In the event that there is not a written “Official Request” the requestor must fill out the section of the form as to the reason for the request, the name of the person whose records are being requested, the record being requested, and any other pertinent information.

1.11  The release of copies or information must be specific, such as “medical record, prescription records, personal identification information, or other document/information”. The information that is requested is “***ONLY***” the minimum amount of information necessary is to be released for the stated purpose.

1.12  If a Law Enforcement Officer or other government official requests to speak with the patient/customer, access is subject to the Laboratory Director’s or designee’ opinion that such access would not impede the patient’s care.

1.13  Upon approval by the Laboratory Director or designee, the patient/customer must be asked whether he/she wants to speak to government official. The patient/customer is not required to speak to the official, and Magnolia Diagnostics will respect the patient/customer’s wishes. This applies even if the customer is an alleged perpetrator of a crime.

1.14  **Mental health, HIV/AIDS, and genetic information may not be disclosed without the written consent of the patient/customer or his/her legal representative.**

2. Judicial & Administrative Proceedings

2.1.  The Laboratory Director or designee may disclose protected health information in the course of any judicial or administrative proceeding, in response to an order of a court or administrative tribunal (to the extent such disclosure is expressly authorized) or in certain conditions in response to a subpoena, discovery request or other lawful process.

2.2.  All request of this type must be submitted to the Laboratory Director who will inform the Magnolia Diagnostics legal counsel, prior to fulfilling these requests.

3. Law Enforcement

3.1 In the event that a member of law enforcement request PHI, the Laboratory Director or designee may release PHI under the following circumstance.

3.1.1  In response to a court order, subpoena, warrant, summons or similar process.

3.1.2  To identify or locate a suspect, fugitive, material witness or missing person.

3.1.3  To identify the victim of a crime, even if unable to unable to obtain the victims’ authorization.

3.1.4  To identify persons or facts regarding a death that is being investigated as a result of criminal conduct.

3.1.5  This list is not meant to be all inclusive, and the Laboratory Director shall use good judgement when responding to all requests for PHI from law enforcement officials.

* 1. Report of Abuse, Neglect or Domestic Violence

4.1  The Laboratory Director or designee may release PHI protected health information to a public health authority that is permitted by law to receive reports of child abuse or neglect, and to notify the appropriate government authority if the Laboratory Director or designee believes the individual has been the victim of abuse, neglect, or domestic violence. Such disclosures will only be made when required or authorized by law.

4.2  Workforce Members are to report any suspicious activity that appears to involve abuse, neglect or domestic violence immediately to the supervisor.

5. Public Health Authorities

5.1. Disclosures of PHI may be released to Public Health Authorities by the Laboratory Director, or designee for the following types of public health concerns or emergency management.

5.1.1  To prevent or control disease, injury or disability.

5.1.2  To report reactions to medications or problems with products.

5.1.3  To notify people of recalls of products they may be using; and to notify a person who may have been exposed to a disease or may be at risk for contracting or spreading a disease or condition.

5.1.4  To avert a serious threat to health or safety.

5.1.5  To prevent or lessen a serious and imminent threat to the health or safety of a person or the public. Any disclosure would be to someone who is able to help prevent the threat.

5.1.6  In response to a natural disaster or other man-mad disaster, where PHI is needed to provide the appropriate care for affected individuals.

6. The Military and Homeland Security

6.1.  Military officials may request PHI for members of the military and for other national security

purposes. All such requests must be handled by the Laboratory Director.

6.2.  PHI may be requested by military or Homeland Security for local or national security and intelligence purposes authorized by the National Security Act, and for protective services of the President and for certain military functions related to federal military personnel as required by military command authorities.

6.3.  The Laboratory Director will have to use discretion and is advised to seek assistance from Magnolia Diagnostics legal counsel for release of PHI about foreign military personnel to the appropriate foreign military authority.

P-103 Disclosure to Personal Representative

Introduction

Magnolia Diagnostics recognizes the rights of patients to appoint a personal representative to inspect and receive a copy of Protected Health Information. A personal representative can be identified as a person who can make healthcare decisions for the patient using a power of attorney or other means that may be determined by state laws and the actions of the patient. An affirmative action taken by a patient in the absence of a power of attorney may include allowing a person who is accompanying the patient, who by the patients’ actions, allows the personal representative to make healthcare decisions for the patient.

The Workforce Member should not attempt to make a determination of the patient and personal representative relationship in terms of the release of PHI. In order for a person or other entity to be deemed a “personal representative” the patient must verbally state this in the presence of the Laboratory Director, or designee, or in writing,

All requests by a patient (or his or her Personal Representative) to access his or her PHI other than review of Magnolia Diagnostics services, shall be submitted in writing, on Magnolia Diagnostics’ “Form- Request for Access”, and delivered to the Laboratory Director for evaluation and response no later than thirty (30) days after Magnolia Diagnostics receives the request. Unless the patient’s request is denied, Magnolia Diagnostics will: (a) arrange for patient’s access to PHI at a convenient time and place, or (b) provide a copy of the PHI in accordance with the patient’s request following payment of the Preparation Costs. If the patient’s request is denied, the Laboratory Director must provide a written explanation to the patient on Magnolia Diagnostics’ “Form- Response to Request for Access”.

The personal representative of a minor child is usually the child’s parent or legal guardian. State laws may affect guardianship. In cases where a custody decree exists, the personal representative is the parent(s) who can make health care decisions for the child under the custody decree. The Laboratory Director must be advised of any situation when the representative of a minor child is in question.

In cases when of a patient death, the personal representative for the deceased is the executor or administrator of the deceased individual’s estate, or the person who is legally authorized by a court or by state law to act on the behalf of the deceased individual or his or her estate. All requests for records of descendants must be directed to the Laboratory Director.

Scope

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director or designee. In some cases, legal counsel must be consulted by the Laboratory Director prior to fulfilling a request for PHI through a personal representative.

1. Process for Patient Rights to be Granted to a Personal Representative

1.1.  Magnolia Diagnostics shall acknowledge Personal Representatives for patient in regards to the access and release of PHI that have submitted any of the following documentation; court order, guardianship, notarized and authenticated statement granting such rights, or approval of a Personal Representative by submission of a “Personal Representative” application (Form PR-100) that is approved by the Laboratory Director, prior to the release of PHI in any form.

1.2.  The Laboratory Director or designee may in their own judgement release certain PHI deemed to be helpful in the care of the patient, to prevent harm and potential drug interactions, or other safety considerations, based on their professional and objective judgment. Workforce Member require authorization from the Laboratory Director or designee prior to a release of PHI under these circumstances.

1. Personal Representatives Rights to Protected Health Information (PHI)

2.1.  Access to their own information, consistent with certain limitations.

2.2.  An accounting of disclosures that Magnolia Diagnostics has made throughout the duration of time that such information is available, subject to availability and other limitations.

2.3.  All requests shall be provided on the “Form-Request for Accounting” and delivered to the Laboratory Director for evaluation and response within sixty (60) days.

2.4.  The accounting period cannot be more than six (6) years prior to the date of the request.

2.5.  An accounting does not have to include any disclosure that Magnolia Diagnostics is not required to document.

2.6.  The Representative may request that the Magnolia Diagnostics restrict uses and disclosure of PHI, which shall be granted on an individual basis by the Laboratory Director.

2.7.  Magnolia Diagnostics shall accommodate reasonable requests by clients or participants or their personal representatives to receive communications by alternative means, such as by mail, e- mail, fax or telephone; and should accommodate reasonable requests by clients or participants or their personal representatives to receive communications at an alternative location.

2.8.  Magnolia Diagnostics may deny access to sensitive health information or health services that must be handled with strict confidentiality under State laws. Magnolia Diagnostics will comply with the more restrictive requirements.

2.9.  All such requests are subject to review by the Laboratory Director.

3. Denial of Access to Protected Health Information

3.1.  Magnolia Diagnostics may deny clients or participants or their personal representatives, with

reasons in writing, access to their own health information if Federal or State law prohibits the disclosure.

3.2.  Under Federal law, clients or participants have the right to access, inspect, and obtain copies of health information on their own cases in Magnolia Diagnostics files or records except for:

3.2.1. Psychotherapy notes; Information compiled for use in civil, criminal, or administrative proceedings; Information that is subject to the Federal Clinical Labs Improvement Amendments of 1988, or exempt pursuant to 42 CFR 493.3(a)(2); Information that, in good faith and using professional judgment, the Laboratory Director or Designee believes could cause harm to the client, participant or to any other person; Documents protected by attorney work-product privilege, and Information where release is prohibited by State or Federal laws.

3.3  Magnolia Diagnostics may deny, with reasons in writing, a request for access made by the client’s or participant’s personal representative for any of the grounds stated above, or if, in good faith and using professional judgment, the Laboratory Director believes that disclosure of such information to the personal representative or to any other person to whom the client or participant has authorized disclosure could cause harm to the client, participant or to any other person, or that the requestor has caused or may cause harm to the client or participant or any other person.

3.4  All requests shall be provided on Magnolia Diagnostics’ “Form-Request for Accounting” and delivered to the Laboratory Director for evaluation and response within sixty (60) days. The accounting period cannot be more than six (6) years prior to the date of the request. An accounting does not have to include any disclosure that Magnolia Diagnostics is not required to document.

3.5  Prior to denial of a request by a patient or a personal representative or anyone else disclosure or access to PHI because there is a good faith belief that disclosure or access could cause harm to the client or participant or to another person, the decision to deny must be made by a licensed health care professional with reasons in writing and DHH must make a review of this denial available to the client/participant and/or requestor. If the requestor wishes to have this denial reviewed, the review must be done by a licensed health care professional who was not involved in the original decision.

References

45 CFR Part l64.522-164.

Section III – Business Associates

B-100 Business Associates Overview

Introduction

The Privacy Rule allows covered providers and health plans to disclose protected health information to these “Business Associates” if the providers or plans obtain satisfactory assurances that the Business Associate will use the information only for the purposes for which it was engaged by the Magnolia Diagnostics, will safeguard the information from misuse, and will help the Magnolia Diagnostics comply with some of the Magnolia Diagnostics’ duties under the Privacy Rule. Covered entities may disclose protected health information to an entity in its role as a Business Associate only to help the Magnolia Diagnostics carry out its health care functions – not for the Business Associate’s independent use or purposes, except as needed for the proper management and administration of the Business Associate.

A “Business Associate” is a person or entity that performs certain functions or activities that involve the use or disclosure of protected health information on behalf of, or provides services to, a Magnolia Diagnostics. A member of the Magnolia Diagnostics’ workforce is not a Business Associate. A covered health care provider, health plan, or health care clearinghouse can be a Business Associate of another Magnolia Diagnostics. The Privacy Rule lists some of the functions or activities, as well as the particular services, that make a person or entity a Business Associate, if the activity or service involves the use or disclosure of protected health information. The types of functions or activities that may make a person or entity a Business Associate include payment or health care operations activities, as well as other functions or activities regulated by the Administrative Simplification Rules.

Business Associate functions and activities include: claims processing or administration; data analysis, processing or administration; utilization review; quality assurance; billing; benefit management; practice management; and repricing. Business Associate services are: legal; actuarial; accounting; consulting; data aggregation; management; administrative; accreditation; and financial. This list is not meant to be exhaustive and the “Business Associate” is defined within the context of 45 CFR 160.103.

A Magnolia Diagnostics’ contract or other written arrangement with its Business Associate must contain the elements specified at 45 CFR 164.504(e). For example, the contract must: Describe the permitted and required uses of protected health information by the Business Associate; Provide that the Business Associate will not use or further disclose the protected health information other than as permitted or required by the contract or as required by law; and Require the Business Associate to use appropriate safeguards to prevent a use or disclosure of the protected health information other than as provided for by the contract. Where a Magnolia Diagnostics knows of a material breach or violation by the Business Associate of the contract or agreement, the Magnolia Diagnostics is required to take reasonable steps to cure the breach or end the violation, and if such steps are unsuccessful, to terminate the contract or arrangement. If termination of the contract or agreement is not feasible, a Magnolia Diagnostics is required to report the problem to the Department of Health and Human Services (HHS) Office for Civil Rights (OCR).

The practical application for determining the need for Business Associate agreements is based on the possession or processing of PHI on behalf of the Magnolia Diagnostics, for which the Business Associate has the same duty to protect the security and integrity of the PHI as the Magnolia Diagnostics.

Scope

All Magnolia Diagnostics Workforce Members shall be responsible for protecting PHI from unauthorized access, use, or disclosure. Except as authorized by the Laboratory Director, no interference with the storage of PHI or any hardware, software, or procedural mechanism that records or examines the activity of electronic PHI (“EPHI”) in Magnolia Diagnostics’ information system shall bepermitted.

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director.

1. Identification of Business Associates

1.1 "Business Associate" is defined as a person or entity that is not part of the Magnolia Diagnostics’ covered workforce and performs certain functions on behalf of Magnolia Diagnostics that involve the use or disclosure of the Magnolia Diagnostics’ Protected Health Information (PHI), including uses for purposes related to payment and/or healthcare operations.

1.1.1 Business Associates functions or activities include: claims processing or administration, data analysis, processing or administration, utilization review, quality assurance, billing, benefit management, practice management, and repricing; or any other function or activity regulated by the Privacy Rule; or legal, actuarial, accounting, consulting, data aggregation, management, administrative, accreditation, or financial services to or for the Magnolia Diagnostics, or to or for an organized health care arrangement in which the Magnolia Diagnostics participates.

1.2  Business Associates do not include an employee of Magnolia Diagnostics ;or other Workforce Members who disclose Protected Health Information for treatment purposes; or any other individuals that the Magnolia Diagnostics considers to be members of its covered workforce; or individuals who may obtain incidental disclosures of Protected Health Information, where access to Protected Health Information is minimal, if at all, and where receipt of such Protected Health Information is not part of the individual's job duties for the Magnolia Diagnostics.

1.3  The Laboratory Director shall provide guidance in determining whether or not a contracted business activity meets the requirements for a Business Associate Agreement

1.3.1 In the event that the Laboratory Director is unable to make the determination as to whether or not the activities and responsibilities of a contracted service requires a Business Associates Agreement, the Laboratory Director shall seek a legal opinion for written guidance.

Business Associates Agreement Execution

2.1. Individuals or entities determined to be business associates of Magnolia Diagnostics must execute a Business Associate Agreement.

2.1.1 Magnolia Diagnostics provides a Business Associate Agreement template for this purpose which can be found in Section III – Business Associates, Form B-101 Sample Business Associates Agreement (HHS).

2.1.2 In the event that a Business Associate provides a Business Associate Agreement for this purpose, it must be equivalent to the terms and conditions of the Magnolia Diagnostics Business Associate Agreement.

2.2.  In the event that a dispute or issues arises from using the Magnolia Diagnostics Business Associate Agreement, the Laboratory Director shall be immediately notified.

2.3.  The Magnolia Diagnostics Business Associate Agreement may be executed only by the designated official of the Magnolia Diagnostics, with oversight provided by the Laboratory Director.

3. Sanctions

3.1.  Workforce Members that are not authorized to enter into contractual agreement(s) on behalf of the Magnolia Diagnostics are subject to disciplinary action, up to and including termination of employment or assignment.

3.2.  Business Associates found to be in violation of policies or laws regarding fulfilling the terms and conditions of the Business Associate Agreement are subject to cancellation of service agreement and may be reported if found to be in violation of HIPAA laws to the appropriate authorities.

Section IV – Security Rule

S-100 HIPAA Security Rule Basics

Introduction

The security standards are divided into the categories of administrative, physical, and technical safeguards as noted in the Security Rule 45 CFR §164.304.

**Administrative Safeguards include**; Security Management Processes, assigned security responsibilities, workforce security, information access management, security awareness and training, security incident procedures, contingency planning, evaluation, and Business Associate Agreements and other related contact management.

**Physical safeguards include**; facility access controls, workstation use, workstation security, and device and media controls.

**Technical Safeguards include**; access control, audit controls, integrity, person or entity authentication, and transmission security.

When the **final Security Rule** was published, the security standards were designed to be “technology neutral” to accommodate changes. The rule does not prescribe the use of specific technologies, so that the health care community will not be bound by specific systems and/or software that may become obsolete. HHS also recognizes that the security needs of covered entities can vary significantly. This flexibility within the rule enables each entity to choose technologies to best meet its specific needs and comply with the standards.

The first standard under Administrative Safeguards section is the Security Management Process. This standard requires covered entities to: “***Implement policies and procedures to prevent, detect, contain and correct security violations***.” The purpose of this standard is to establish the administrative processes and procedures that a covered entity will use to implement the security program in its environment. There are four implementation specifications in the Security Management Process standard.

Risk Analysis (Required) § 164.308(a)(1)(ii)(A): The Risk Analysis implementation specification requires covered entities to: “***Conduct an accurate and thorough assessment of the potential risks and vulnerabilities to the confidentiality, integrity, and availability of electronic protected health information held by the covered entity***.”

Risk Management (Required) § 164.308(a)(1)(ii)(B): Risk Management is a required implementation specification. It requires an organization to make decisions about how to address security risks and vulnerabilities. The Risk Management implementation specification states that covered entities must: “***Implement security measures sufficient to reduce risks and vulnerabilities to a reasonable and appropriate level to comply with §164.306(a***).”

Sanction Policy (Required) § 164.308(a)(1)(ii)(C) Another implementation specification in the Security Management Process is the Sanction Policy. It requires covered entities to: “Apply appropriate sanctions against workforce members who fail to comply with the security policies and procedures of the covered entity.” Appropriate sanctions must be in place so that workforce members understand the consequences of failing to comply with security policies and procedures, to deter noncompliance.

Information System Activity Review (Required) § 164.308(a)(1)(ii)(D) The Security Management Process standard also includes the Information System Activity Review implementation specification. This required implementation specification states that covered entities must: “**Implement procedures to regularly review records of information system activity, such as audit logs, access reports, and security incident tracking reports**.”

In the following policies of the Security Rule Section, there are many straightforward actions that Workforce Members accomplish on a daily basis to assist the organization with maintaining security of Protected Health Information (PHI) and the systems that are used for access, storage and transmission of PHI data. It is important that Workforce members take person responsibility to ensuring that the organization is not left venerable by logging off or shutting down work stations, protecting passwords, and reporting any unusual activity to the Laboratory Director.

There are also many technical standards that workforce members may not have sufficient experience to manage, such as making sure that security software updates are made on a timely basis or that audits are completed on the security systems used to protect the PHI data. Workforce Members are encouraged to ask questions, and work with their supervisors and the Laboratory Director to create a culture of security to protect the integrity of the PHI we are entrusted with by our patients/customers.

Magnolia Diagnostics must not rely solely on security systems provided by others such as; providers, hospitals, payers and other covered entities for which the Magnolia Diagnostics receives or transmits PHI to meet the requirements of the Security Rule. The Magnolia Diagnostics must implement and maintain security measures to ensure the integrity of the systems used by the Magnolia Diagnostics, and for those in which the Magnolia Diagnostics interacts through to maintain compliance with the Security Rule.

Scope

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. This policy provides the framework for Section IV – the Security Rule. In the event it is not clear if this policy applies to you, please contact the Laboratory Director or designee.

1. Administrative Safeguards

1.1.  Magnolia Diagnostics is covered by the Security Rule provisions of the Health Insurance

Portability and Accountability Act (HIPAA).

1.2.  The Magnolia Diagnostics must maintain administrative safeguards which require actionable policies and procedures to take appropriate and timely administrative actions, and to prevent, detect, contain, and correct security violations.

1.3.  Administrative safe guards must involve the selection, development, implementation, and maintenance of security measures to protect PHI and to manage the conduct of Workforce Members in relation to the protection of that information.

1.4.  A central requirement is that you perform a security risk analysis that identifies and analyzes risks to PHI and then implement security measures to reduce the identified risks.

1.5.  Where the Privacy Rule requires patient authorization, voluntary consent is not sufficient to permit a use or disclosure of protected health information unless it also satisfies the requirements of a valid authorization. An authorization is a detailed document that gives covered entities permission to use protected health information for specified purposes, which are generally other than treatment, payment, or health care operations, or to disclose protected health information to a third party specified by the individual.

2. Physical Safeguards

2.1  Safe guards are physical measures, policies, and procedures to protect electronic information systems and related buildings and equipment from natural and environmental hazards and unauthorized intrusion.

2.2  The Magnolia Diagnostics must limit physical access to its facilities while ensuring that authorized access is allowed.

2.3  The Magnolia Diagnostics must implement policies and procedures to specify proper use of and access to workstations and electronic media.

2.4  The Magnolia Diagnostics must have in place policies and procedures regarding the transfer, removal, disposal, and re-use of electronic media, to ensure appropriate protection of electronic protected health information (e-PHI).

1. Technology Safeguards

3.1 The Magnolia Diagnostics must implement technical policies and procedures that allow only authorized persons to access electronic protected health information (e-PHI).

3.2 The Magnolia Diagnostics must implement hardware, software, and/or procedural mechanisms to record and examine access and other activity in information systems that contain or use e- PHI.

3.3 The Magnolia Diagnostics must implement policies and procedures to ensure that e-PHIis not improperly altered or destroyed, which includes electronic measures.

3.4 The Magnolia Diagnostics must implement technical security measures that guard against unauthorized access to e-PHI that is being transmitted over an electronic network.

1. Organizational Standards

4.1  The Magnolia Diagnostics is required to comply with every Security Rule "Standard." However, the Security Rule categorizes certain implementation specifications within those standards as "addressable," while others are "required."

4.1.1  The "required" implementation specifications must be implemented. The "addressable" designation does not mean that an implementation specification is optional.

4.1.2  The Magnolia Diagnostics is permitted to determine whether the addressable implementation specification is reasonable and appropriate. If it is not, the Security Rule allows the Magnolia Diagnostics to adopt an alternative measure that achieves the purpose of the standard, if the alternative measure is reasonable and appropriate.

4.2  The Laboratory Director must maintain Organizational Standards for the Security Rule through policies and procedures, ongoing risk analysis, implementation and maintenance of access guidelines and rules, and enlistment of the necessary resources to ensure compliance with the Security Rule. Lack of resources is an unacceptable cause of a PHI breach or security vulnerability.

4.3  The Security Rule standards requires the Magnolia Diagnostics to have contracts or other arrangements with Business Associates that will have access to the Magnolia Diagnostics’ PHI.

4.4  The standards provide the specific criteria required for written contracts or other arrangements that involve Business Associates (BA) and PHI that is transmitted, stored, disposed of, or accessed between the BA and the Magnolia Diagnostics.

4.5  If the Magnolia Diagnostics knows or becomes aware of an activity or practice of the business associate that constitutes a material breach or violation of the business associate’s obligation, the Laboratory Director must take reasonable steps to cure the breach or end the violation.

4.5.1  Violations include the failure of Business Associates to implement safeguards that reasonably and appropriately protect e-PHI.

4.5.2  The Laboratory Director is to maintain an ongoing knowledge of the Security Rule the Department of Health and Human Services national standards for confidentiality, integrity and availability of e-PHI.

4.5.3  The Department of Health and Human Services (HHS), Office for Civil Rights (OCR) is responsible for administering and enforcing these standards, in concert with its enforcement of the Privacy Rule, and may conduct complaint investigations and compliance reviews.

5. Policies and Procedures

5.1. Magnolia Diagnostics is required to adopt reasonable and appropriate policies and procedures to comply with the provisions of the Security Rule.

5.2.  The Magnolia Diagnostics must maintain, until six years after the date of their creation or last effective date (whichever is later), written security policies and procedures and written records of required actions, activities, or assessments.

5.3.  The Magnolia Diagnostics Laboratory Director must periodically review and update its documentation in response to environmental or organizational changes that affect the security of PHI and approve all changes to the written policies regarding the Security Rule, and provide the necessary updates and training to Workforce Members.

6. Risk Analysis

6.1  Magnolia Diagnostics must ensure that the Laboratory Director has sufficient knowledge and access to tools and resources (internal and/or external) for conducting ongoing risk analysis.

6.2  The risk analysis must include; information systems that include hardware, software, information, data, applications, communications, and people (Workforce Members and Business Associates).

6.2.1  The risk analysis process includes, but is not limited to, the following activities: evaluate the likelihood and impact of potential risks to e-PHI; Implement appropriate security measures to address the risks identified in the risk analysis; document the chosen security measures and, where required, the rationale for adopting those measures; and maintain continuous, reasonable, and appropriate security protections.

6.2.2  The risk analysis must be completed on no less than an annual basis, and it is highly recommended that periodic reviews of the effectiveness of the policies and

7. State Guidelines

States have additional guidelines for E-Prescribing that the Magnolia Diagnostics must incorporate into the Security Rule policies. See QC-3 HIPAA State Guidelines.

Resources

U.S. Department of Health and Human Services, Summary of the HIPAA Rule (expiration date 8/31/2017).

The Office of the National Coordinator for Health Information Technology, Guide to Privacy and Security of Electronic Health Information.

S-101 Administrative Safeguards

Introduction

All Medical Office personnel shall be responsible for protecting PHI from unauthorized access, use, or disclosure. Except as authorized by the Laboratory Director or designee, no interference with the storage of PHI or any hardware, software, or procedural mechanism that records or examines the activity of electronic PHI (“EPHI”) in the Medical Office’s information system shall be permitted.

Scope

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director.

1. Security Management Processes

1.1.  The Laboratory Director shall maintain and update the security management processes to be proactive and respond to any changes in the information technology environment that poses a threat to the security and integrity of Protect Health Information (PHI) and the systems that are used to store, transmit, receive, visualize or dispose of PHI.

1.2.  Shall identify and deploy resources sufficient to support the Laboratory Director to carry out these duties in a timely manner.

1.3.  In collaboration with the Laboratory Director assign security responsibilities to the appropriate staff or qualified outside vendor(s).

1.3.1. Qualified vendors must be willing and capable of entering into a Business Associate Agreement as applicable and have the necessary resources to complete assigned responsibilities in accordance with HIPAA rules.

1.4.  Shall have the final approval for the policies and procedures for HIPAA compliance.

1.5.  Shall maintain signature authority for entering into service agreements with Business Associates with input from the Laboratory Director.

1.6.  Shall employ or contract with individuals or companies that have sufficient knowledge and resources to assemble and maintain a high security data system, with a major emphasis on security, malware and virus protection and access controls.

1.7.  The Laboratory Director shall create, review and update policies relating to HIPAA privacy and security on an ongoing basis, along with tools and methods to periodically test the effectiveness of the policies and the technology security.

1.8.  The Laboratory Director shall ensure that workforce members are properly training prior to having access to PHI or systems that contain PHI.

1.9.  The Laboratory Director or designee shall assign usernames and passwords to all staff that require access to Medical Office information systems.

1.10.  The Laboratory Director shall maintain policies and processes on control of paper documents to ensure that workforce members are diligent in their producing, handling, utilizing, transporting, and disposing of PHI properly.

1.11.  The Laboratory Director shall establish and maintain security incident procedures to include notifications to affected individuals, the media and the Secretary of HHS in the event of a Breach.

1.12.  The Laboratory Director shall review all Business Associate Agreements and assign verification of liability insurance.

1.13.  The Laboratory Director shall make periodic reviews of Business Associates compliance with security standards through direct observation, audit, or annual performance review.

1.14.  The Laboratory Director shall conduct risk assessments for emergency planning and contingency planning in collaboration with, key Workforce Members and community resources as appropriate. The risk assessment shall be completed on no less than an annual basis, to include updating of contingency plans.

S-102 Physical Safeguards

Introduction

The Security Rule defines Physical safeguards are physical measures, policies, and procedures to protect a covered entity’s electronic information systems and related buildings and equipment from natural and environmental hazards, and unauthorized intrusion. The standards under physical safeguards include facility access controls, workstation use, workstation security, and device and media controls. The Security Rule requires covered entities to implement physical safeguard standards for their electronic information systems whether such systems are housed on the covered entity’s premises or at another location.

Scope

All Magnolia Diagnostics Workforce Members shall be responsible for protecting PHI from unauthorized access, use, or disclosure. Except as authorized by the Laboratory Director, no interference with the storage of PHI or any hardware, software, or procedural mechanism that records or examines the activity of electronic PHI (“EPHI”) in Magnolia Diagnostics ’s information system shall be permitted.

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director.

1. Physical Safeguards

1.1.  Magnolia Diagnostics shall designate specific Workforce Members and/or Business Associates that are responsible for installing and maintaining physical safeguards.

1.2.  AllWorkforceMembersandBusinessAssociatesshalltakeappropriatemeasurestoapplyphysical safeguards to their work area and electronic devices to avoid unauthorized access to PHI and data systems.

1.3.  PhysicalsafeguardsofPHIincludeprotectingPHIfromaccidentalorintentionalunauthorizeduseor disclosure, which includes; safeguarding sensitive information, user names, passwords, updated security software, safe browsing habits, securing desktop and mobile devices, use of screen savers, protection against theft of devices in public areas, and security of servers and data transmission routes.

1.4.  Physical access includes limiting accidental disclosures such as discussion in open areas, leaving PHI in plain view, or discussion PHI with patients and their authorized representatives in close proximity to others.

1.5.  Physical safeguards must include physical access controls to areas where PHI is stored or inuse, by keep indoors, cabinets, windows, and other access points locked and protected from unauthorized entry.

2. Facility Access Controls

2.1.  Magnolia Diagnostics shall provide warning signs of restricted areas in plain view of the general public.

2.2.  Magnolia Diagnostics shall provide surveillance cameras and security systems to record access to restricted areas and to notify law enforcement in the event of a beach in physical security.

2.3.  Workforce Members are to be identified with Identification Badges that are to be worn at all times while on Magnolia Diagnostics premises.

2.3.1.Identification Badges that allow for access to restricted areas are to be secured by Workforce Member when not in use.

2.3.2.Loss of Identification Badges are to be immediately reported to the Laboratory Director or designee.

2.4. Business Associates must be properly identified when accessing restricted areas.

2.4.1.Workforce Members are to prevent access of Business Associates staff that cannot be properly identified from accessing restricted areas, which if necessary may include notification of the Laboratory Director or law enforcement.

2.4.2.  Business Associates must be escorted when accessing restricted areas by an authorized Workforce Member.

2.4.3.  A written log or equivalent must be used to identify the date, time, person, and reason for access to restricted areas.

2.5. The Laboratory Director or designee shall maintain a method of validating access controls to physical locations, data systems, and software programs.

2.5.1. The Laboratory Director must have a method for maintaining a record of access to physical locations that use electronic badges, and for all electronic access to systems. Equipment, and software where there is access to PHI or systems that store or transmit PHI.

2.6.  The Laboratory Director or designee shall have a method of immediately restricting access to electronic access to systems, equipment, and software where there is access to PHI or systems that store or transmit PHI.

2.7.  Repairs and updates to access controls must be documented in a log or equivalent, to include the date, time, person making the repair or update, and the reason for the repair or update.

3. Workstations, Email and Data Storage Accounts

3.1.  A workstation is defined as “an electronic computing device, for example, a laptop or desktop computer, or any other device that performs similar functions, and has electronic media stored in its immediate environment.

3.2.  Workstations must have access controls such as passwords and/or authentication for access.

3.3.  Screen savers shall be used to automatically restrict access when systems or devices are not in use.

3.4.  All access controls and restrictions apply to all workstations accessed outside of the Magnolia Diagnostics premises, such as remote access in any form or format.

3.4.1. Remote access must be approved by the Laboratory Director or designee in advance of such access.

3.5.  Email and data storage accounts must be authorized for individual use by the Laboratory Director or designee.

3.6.  Magnolia Diagnostics email accounts shall not be used for personal business, auto- forwarded, or stored in cloud-based accounts (i.e. Google Drive or Drobox) or external hard drives, without the expressed written permission of the Laboratory Director or designee.

3.7.  Passwords for email and authorized data storage accounts are to be kept private and not shared with others.

3.7.1.In the event that password(s) is (are) compromised, the Laboratory Director or Designee is to be immediately notified.

3.7.2.Passwords and access is to be immediately restricted upon suspension and voluntary or involuntary termination of employment or assignment.

3.7.3.Single Sign-on (SSO) access must be approved by the Laboratory Director or designee.

3.7.4.Passwords are not to be disclosed verbally or electronically with others.

3.7.5. Sharing of password(s) with others is grounds for disciplinary action.

3.8. Workforce Members must log-off of all devices when not in use.

4. Loss of Data or Devices

4.1.  Any loss of data, such as loss of external or internal hard drives, successful hacking attempts, physical loss of equipment and devices are to be immediately reported to the Laboratory Director or designee.

4.2.  A record that includes identification of all devices that provide and/or are authorized for use must be maintained by the Laboratory Director or designee.

4.2.1. Records must be updated whenever there is an addition, loss, discontinuance or disposal of data access and storage devices.

4.2.2. Devises that are recycled or disposed of must be managed to remove all identifiable PHI and means of access according to Section V – Disposal policies and procedures.

5. Sanctions

5.1.  Workforce Members that do not follow policies for maintaining the security and integrity of physical safeguards, are subject to disciplinary action, up to and including termination of employment or assignment.

5.2.  Business Associates found to be in violation of physical safeguard policies and/or do not ensure the security and integrity of physical safeguards are subject to cancellation of service agreement and may be reported if found to be in violation of HIPAA laws to the appropriate authorities.

S-103 Technical Safeguards

Introduction

The Security Rule defines technical safeguards in § 164.304 as “the technology and the policy and procedures for its use that protect electronic protected health information and control access to it.” The Security Rule is based on the fundamental concepts of flexibility, scalability and technology neutrality. Therefore, no specific requirements for types of technology to implement are identified. The Rule allows a Magnolia Diagnostics to use any security measures that allows it reasonably and appropriately to implement the standards and implementation specifications. The Magnolia Diagnostics must determine which security measures and specific technologies are reasonable and appropriate for implementation.

45 CFR § 164.306(b), the Security Standards: General Rules, Flexibility of Approach, provides key guidance for focusing compliance decisions, including factors a covered entity must consider when selecting security measures such as technology solutions. In addition, the results of the required risk analysis and risk management processes at §§ 164.308(a)(1)(ii)(A) & (B) will also assist the entity to make informed decisions regarding which security measures to implement. The Security Rule does not require specific technology solutions.

There are many technical security tools, products, and solutions that a covered entity may select. Determining which security measure to implement is a decision that a Magnolia Diagnostics must make based on what is reasonable and appropriate for their specific organization, given their own unique characteristics, as specified in § 164.306(b) the Security Standards: General Rules, Flexibility of Approach. Some solutions may be costly, especially for smaller Pharmacies. While cost is one factor a Magnolia Diagnostics may consider when deciding on the implementation of a particular security measure, it is not the only factor. The Security Rule is clear that reasonable and appropriate security measures must be implemented, see 45 CFR 164.306(b), and that the General Requirements of § 164.306(a) must be met.

Magnolia Diagnostics Access Control Standards include four specifications; Unique User Identification (Required), Emergency Access Procedure (Required), Automatic Logoff (Addressable), Encryption and Decryption (Addressable).

Scope

All Magnolia Diagnostics Workforce Members shall be responsible for protecting PHI from unauthorized access, use, or disclosure. Except as authorized by the Laboratory Director, no interference with the storage of PHI or any hardware, software, or procedural mechanism that records or examines the activity of electronic PHI (“EPHI”) in Magnolia Diagnostics’ information system shall be permitted.

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director.

1. Unique User Identification

1.1.  Magnolia Diagnostics. shall designate a unique user identification name for Workforce Members and/or Business Associates that access systems and data.

1.2.  The username may include a first name, initials, last name, and a number or any combination thereof.

1.3.  The unique user identification shall be used to track specific activity when the user is logged into the Magnolia Diagnostics or Business Associate domain and information systems.

1.4.  The password associated with the unique user identification shall not contain the name of the person, or easy to identify sequences of letters or numbers.

1.5.  The password shall contain at a minimum; a capitalized letter, a number, and a symbol (if permitted).

1.6.  The password shall be challenging for hackers and unauthorized users to assist in preventing unauthorized access.

1. Software and Hardware

2.1.  All software and hardware purchases must receive pre-approval by the Laboratory Director or designee and must follow a consistent documented request process.

2.2.  Use of hardware and all other devices capable of receiving, storing and transmitting PHI must receive prior approval and must follow a consistent documented request process.

2.3.  Use of personal electronic devices that have not received written authorization for use by the Laboratory Director or designee is strictly forbidden.

2.3.1.Use of personal electronic devices without prior authorization may result in disciplinary action, up to and including termination of employment.

2.4. Installation of unauthorized software is strictly forbidden.

2.4.1.Only properly licensed, obtained and approved software may be installed on computers that use, store, or come in contact with electronic protected health information (ePHI).

2.5.  Business Associates must have safeguards, policies and processes in place that meet the security standard requirements.

2.6.  Unauthorized duplication or distribution of Magnolia Diagnostics-licensed software is strictly prohibited.

2.7. The Laboratory Director must approve use of custom-built applications.

1. Virus and Malware Protection

3.1.  Workforce Members are required to avoid downloading from unknown sources as they may contain malicious software, social engineering acts and hoaxes are designed to disrupt computer systems, gather information that leads to loss of privacy or exploitation, or gain unauthorized access to system resources.

3.2.  All Magnolia Diagnostics information systems, including servers, desktop computers, laptop and other devices accessing the Magnolia Diagnostics’ information systems and databases must have an automated anti-malware management system. Disabling, altering, deleting, or preventing these programs or other security settings from updating is strictly prohibited.

3.3.  The deliberate creation, use, storage, distribution, and/or possession of malware is expressly prohibited. The intentional storage, distribution, and/or possession of malware may be construed as failure to safeguard information systems.

3.4.  Removal of unauthorized software: Unauthorized, malicious or nuisance software can be installed on a computer without the knowledge of the user. If unauthorized software is discovered to be or suspected to be installed on any system, the Laboratory Director or designee must be contacted immediately.

3.5.  Workforce Members shall not use information systems to send unsolicited or bulk advertisements or commercial messages. Workforce Members Users shall take due care when opening suspicious or unexpected email with attachments from unknown users. When uncertain, users shall contact the Laboratory Director or designee for assistance and/or guidance.

3.6.  Users of information systems must recognize and avoid social engineering links. Users should not engage in requested actions, whether that is a human or electronic request, without knowing the requested information and the person making the request. Workforce Members are required to inform the Laboratory Director or designee prior to acceptance.

.

3.7.  Creation or forwarding of hoax messages is expressly prohibited. Workforce Members who receive virus-related warnings are required to inform the Laboratory Director or designee.

3.8.  System administrators may remove, with or without prior notification any malicious or unauthorized software.

1. Remote Access

4.1.  Remote access requires prior approval of the Laboratory Director or designee.

4.2.  Remote access to information systems must be managed and protected by Workforce Members who are granted remote access.

1. Emergency Access Procedures  
   5.1. The Magnolia Diagnostics shall maintain a method to provide services during an emergency that limits or prevents access to information systems and/or devices.

5.1.1.In the event that an emergency or disaster’s severity prevents access to vital data that is required for providing services to patients and their representatives, the on-duty manager shall seek guidance from the Laboratory Director (if available) and should use good and reasonable judgement for any services provided during an emergency or disaster.

5.1.2.The on-duty manager or designee shall maintain a written record of all services provided during an emergency or disaster.

5.2. In the event of an emergency that prevents access to systems and data, please refer to Section VI – Disaster Preparedness and Response.

1. Automatic Logoff

6.1.  The Magnolia Diagnostics shall maintain an automatic log off for all systems and devices used that stores or transmits PHI data.

6.2.  The Laboratory Director or designee shall determine the maximum amount of time for systems and devices to automatically logoff, which must not exceed fifteen (15) minutes to activate a timeout or open a secure screen that requires the user to log back in.

1. Encryption and Decryption

7.1.  Encryption is the process of transforming information using an algorithm to make data unreadable to anyone except those possessing special knowledge; often referred to as a key or password.

7.2.  Magnolia Diagnostics shall adhere to the US National Institute of Standards and Technology for encryption and decryption data management.

8. Sanctions

8.1.  Workforce Members that do not follow policies for maintaining the security and integrity of physical safeguards, are subject to disciplinary action, up to and including termination of employment or assignment.

8.2.  Business Associates found to be in violation of physical safeguard policies and/or do not ensure the security and integrity of physical safeguards are subject to cancellation of service agreement and may be reported if found to be in violation of HIPAA laws to the appropriate authorities.

S-104 Storage, Transport, Transfer and Transmission

Introduction

In order to determine the technical security measures to implement to comply with this standard, Magnolia Diagnostics must review the current methods used to transmit EPHI. When EPHI transmitted through email, over the Internet, or via some form of private or point-to-point network, Magnolia Diagnostics must identify the available and appropriate means to protect EPHI as it is stored, transported, transferred or transmitted. Paper documents are often scanned, faxed or downloaded in electronic formats. Magnolia Diagnostics maintains paper documents and labels containing PHI that must be given the same security considerations.

Scope

All Magnolia Diagnostics Workforce Members shall be responsible for protecting PHI from unauthorized access, use, or disclosure. Except as authorized by the Laboratory Director, no interference with the storage of PHI or any hardware, software, or procedural mechanism that records or examines the activity of electronic PHI (“EPHI”) in Magnolia Diagnostics ’s information system shall be permitted. This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director. This policy applies to electronic protected health information (ePHI) while the data is in transit over an electronic communications network and when the transmission is initiated by Magnolia Diagnostics All applications that transfer ePHI over an electronic communications network (e.g., email, file transfer, web browser) are subject to this policy.

1. Storage of Data (ePHI)

1.1.  All data containing PHI shall be software and hardware purchases must receive pre-approval by the

Laboratory Director or designee and must follow a consistent documented request process.

1.2.  Use of hardware and all other devices capable of receiving, storing and transmitting PHI must receive prior approval and must follow a consistent documented request process.

1.3.  Use of personal electronic devices that have not received written authorization for use by the Laboratory Director or designee is strictly forbidden.

1.3.1. Use of personal electronic devices without prior authorization may result in disciplinary action, up to and including termination of employment.

1.4. Installation of unauthorized software is strictly forbidden.

1.4.1. Only properly licensed, obtained and approved software maybe installed on computers that use, store, or come in contact with electronic protected health information (ePHI).

1.5. Business Associates must have safeguards, policies and processes in place that meet the security standard requirements.

1.6.  Unauthorized duplication or distribution of Magnolia Diagnostics-licensed software is strictly prohibited.

1.7.  The Laboratory Director must approve use of custom-built applications.

1. Emergency Access Procedures  
   2.1. Magnolia Diagnostics shall maintain a method to provide services during an emergency that limits or prevents access to information systems and/or devices.

2.1.1.  Intheeventthatanemergencyordisaster’sseveritypreventsaccesstovitaldatathatisrequired for providing services to patients and their representatives, the on-duty Manager shall seek guidance from the Laboratory Director (if available) and should use good and reasonable judgement for any services provided during an emergency or disaster.

2.1.2.  The Manager or designee shall maintain a written record of all services provided during an emergency or disaster.

2.2. In the event of an emergency that prevents access to systems and data, please refer to Section VI – Disaster Preparedness and Response.

1. Automatic Logoff

3.1.  The Magnolia Diagnostics shall maintain an automatic logoff for all systems and devices used that stores or transmits PHI data.

3.2.  The Laboratory Director or designee shall determine the maximum amount of time for systems and devices to automatically logoff, which must not exceed fifteen (15) minutes to activate a timeout or open a secure screen that requires the user to log back in.

1. Encryption and Decryption

4.1.  Encryption is the process of transforming information using an algorithm to make data unreadable to anyone except those possessing special knowledge; often referred to as a key or password.

4.2.  Magnolia Diagnostics shall adhere to the US National Institute of Standards and Technology for encryption and decryption data management.

5. Sanctions

5.1.  Workforce Members that do not follow policies for maintaining the security and integrity of physical safeguards, are subject to disciplinary action, up to and including termination of employment or assignment.

5.2.  Business Associates found to be in violation of physical safeguard policies and/or do not ensure the security and integrity of physical safeguards are subject to cancellation of service agreement and may be reported if found to be in violation of HIPAA laws to the appropriate authorities.

Section V – Disposal

D-100 Disposal of Printed PHI

Introduction

The HIPAA Privacy Rule requires that the appropriate administrative, technical, and physical safeguards are always in place and available to protect the privacy of protected health information (PHI), in any form as stated in 45 CFR 164.530(c). The Magnolia Diagnostics must implement reasonable safeguards to limit incidental, and avoid prohibited, uses and disclosures of PHI, including the disposal of such information. The HIPAA Security Rule requires the Magnolia Diagnostics to implement policies and procedures to address the final disposition of electronic PHI and/or the hardware or electronic media on which it is stored, as well as to implement procedures for removal of electronic PHI from electronic media before the media are made available for re-use per 45 CFR 164.310(d)(2)(i) and (ii). Failing to implement reasonable safeguards to protect PHI in connection with disposal could result in impermissible disclosures of PHI and may result in significant HIPAA breaches subject to penalties and fines.

The Magnolia Diagnostics must ensure that Workforce Members receive training on and follow the disposal policies and procedures of the Magnolia Diagnostics, as necessary and appropriate for each workforce member as noted in 45 CFR 164.306(a)(4), 164.308(a)(5), and 164.530(b) and (i). Therefore, any workforce member involved in disposing of PHI, or who supervises others who dispose of PHI, must receive training on disposal. This includes any volunteers. See 45 CFR 160.103 (definition of “workforce”).

The Magnolia Diagnostics is not permitted to simply abandon PHI or dispose of it in dumpsters or other containers that are accessible by the public or other unauthorized persons. However, the Privacy and Security Rules do not require a particular disposal method. The Magnolia Diagnostics must review their own circumstances to determine what steps are reasonable to safeguard PHI through disposal, and develop and implement policies and procedures to carry out those steps. In determining what is reasonable, the Magnolia Diagnostics should assess potential risks to patient privacy, as well as consider such issues as the form, type, and amount of PHI to be disposed. For instance, the disposal of certain types of PHI such as name, social security number, driver’s license number, debit or credit card number, diagnosis, treatment information, or other sensitive information may warrant more care due to the risk that inappropriate access to this information may result in identity theft, employment or other discrimination, or harm to an individual’s reputation.

In general, examples of proper disposal methods may include, but are not limited to:

For PHI in paper records, shredding, burning, pulping, or pulverizing the records so that PHI is rendered essentially unreadable, indecipherable, and otherwise cannot be reconstructed.

Maintaining labeled prescription bottles and other PHI in opaque bags in a secure area and using a disposal vendor as a business associate to pick up and shred or otherwise destroy the PHI.

For PHI on electronic media, clearing (using software or hardware products to overwrite media with non-sensitive data), purging (degaussing or exposing the media to a strong magnetic field in order to disrupt the recorded magnetic domains), or destroying the media (disintegration, pulverization, melting, incinerating, or shredding).

Scope

All Magnolia Diagnostics Workforce Members shall be responsible for protecting PHI from unauthorized access, use, or disclosure. Except as authorized by the Laboratory Director, no interference with the storage of PHI or any hardware, software, or procedural mechanism that records or examines the activity of electronic PHI (“EPHI”) in Magnolia Diagnostics’ information system shall be permitted.

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director.

1. Printed Protected Health Information (PHI)

1.1.  Printed material which includes PHI may be found in the following documents, labels or other printed media: customer encounter forms and labels, printouts from IS systems containing PHI, Magnolia Diagnostics notes, index cards or worksheets with customer’s information, photocopies of customer’s insurance cards, customer’s information on Post-It notes, personal reminders, emails, memos, telephone call logs, and other written communications that contain PHI. This list is not meant to be all inclusive.

1.2.  Documents that contain PHI which are subject to retention requirements, should be managed carefully to not expose PHI while in use, storage or transportation.

1.3.Workforce Members are prohibited from destroying, altering, or discarding any information (with or without PHI) which may be subject to government investigations, audit, subpoenas, and search warrants. Standard document disposal policies and destruction procedures should be immediately suspended once there is notification that the documents are part of a government investigation, or a subpoena or search warrant has been served.

1.4.  Printed materials containing PHI that are not subject to retention requirements, must be destroyed or de-identified by an approved method. It is strictly prohibited to discard PHI into wastebaskets, recycling bins or other accessible locations or containers.

1.5.  Printed materials containing PHI that can be shredded or de-identified, must be kept in a locked container prior to transport and disposal.

1.6.In the event that there is insufficient space or lockable containers available for storage prior to destruction or de-identification, the Laboratory Director or designee is to be contacted for a resolution, and the materials kept secure, until the issue is resolved.

1. De-Identification Standard and Methods

2.1.  Section 164.514(a) of the HIPAA Privacy Rule provides the standard for de-identification of protected health information. Under this standard, health information is not individually identifiable if it does not identify an individual and if the Magnolia Diagnostics has no reasonable basis to believe it can be used to identify an individual.

2.2.  Sections164.514(b)and(c)ofthePrivacyRulecontaintheimplementationspecificationsthatacovered entity must follow to meet the de-identification standard.

2.3.  ThePrivacyRuleprovidestwomethodsbywhichhealthinformationcanbedesignatedasde-identified zwhich is Expert Determination and Safe Harbor.

2.4.  The Expert Determination method requires a person with appropriate knowledge of and experience with generally accepted statistical and scientific principles and methods for rendering information not individually identifiable: (i) Applying such principles and methods, determines that the risk is very small that the information could be used, alone or in combination with other reasonably available information, by an anticipated recipient to identify an individual who is a subject of the information; and (ii) Documents the methods and results of the analysis that justify such determination.

2.5.  TheSafeHarborMethodrequiresthatnopartsorderivativesofanyofthelistedidentifiersbedisclosed in healthcare data. This method may be used by the Magnolia Diagnostics, through a third party, or a Workforce Member that has the expertise and equipment to complete this operation.

2.5.1.The Laboratory Director must pre-approve any Workforce Member or outside company that is utilized for de-identification.

2.6. In general, examples of proper disposal methods may include, but are not limited to:

2.6.1.For PHI in paper records, shredding, burning, pulping, or pulverizing the records so that PHI is rendered essentially unreadable, indecipherable, and otherwise cannot be reconstructed.

2.6.2.Maintaining labeled prescription bottles and other PHI in opaque bags in a secure area and using a disposal vendor as a business associate to pick up and shred or otherwise destroy the PHI.

2.6.3.For PHI on electronic media, clearing (using software or hardware products to overwrite media with non-sensitive data), purging (degaussing or exposing the media to a strong magnetic field in order to disrupt the recorded magnetic domains), or destroying the media (disintegration, pulverization, melting, incinerating, or shredding).

3. Certificates of Destruction

3.1.  All materials that contain PHI and are sent out to a contractor for disposal or de-identification, in bulk form, must be identified when destroyed with a Certificate of Destruction.

3.2.  Internal methods for destroying or de-identification of material that contain PHI must be approved by the Laboratory Director.

4. Sanctions

4.1.  Workforce Members that do not follow policies for disposal of printed PHI are subject to disciplinary

action, up to and including termination of employment or assignment.

4.2.  Business Associates found to be in violation of policies or laws regarding disposal or de- identification are subject to cancellation of service agreement and may be reported if found to be in violation of HIPAA laws to the appropriate authorities.

D-101 Disposal of Electronic PHI

Introduction

The HIPAA Privacy Rule requires that the Magnolia Diagnostics applies appropriate administrative, technical, and physical safeguards to protect the privacy of protected health information (PHI), in any form as stated in 45 CFR 164.530(c). The Magnolia Diagnostics must implement reasonable safeguards to limit incidental, and avoid prohibited, uses and disclosures of PHI, including the disposal of such information. The HIPAA Security Rule requires the Magnolia Diagnostics to implement policies and procedures to address the final disposition of electronic PHI and/or the hardware or electronic media on which it is stored, as well as to implement procedures for removal of electronic PHI from electronic media before the media are made available for re-use per 45 CFR 164.310(d)(2)(i) and (ii). Failing to implement reasonable safeguards to protect PHI in connection with disposal could result in impermissible disclosures of PHI and may result in significant HIPAA breaches subject to penalties and fines.

The Magnolia Diagnostics must ensure that Workforce Members receive training on and follow the disposal policies and procedures of the Magnolia Diagnostics, as necessary and appropriate for each workforce member as noted in 45 CFR 164.306(a)(4), 164.308(a)(5), and 164.530(b) and (i). Therefore, any workforce member involved in disposing of PHI, or who supervises others who dispose of PHI, must receive training on disposal. This includes any volunteers. See 45 CFR 160.103 (definition of “workforce”).

The proper methods for destruction of PHI on electronic media includes, clearing (using software or hardware products to overwrite media with non-sensitive data), purging (degaussing or exposing the media to a strong magnetic field in order to disrupt the recorded magnetic domains), or destroying the media (disintegration, pulverization, melting, incinerating, or shredding). Please refer to Policy D-100 Disposal of Printed PHI for a complete introduction to the destruction and de-identification of PHI.

Scope

All Magnolia Diagnostics Workforce Members shall be responsible for protecting PHI from unauthorized access, use, or disclosure. Except as authorized by the Laboratory Director, no interference with the storage of PHI or any hardware, software, or procedural mechanism that records or examines the activity of electronic PHI (“EPHI”) in Magnolia Diagnostics’ information system shall be permitted.

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director.

1. Disposal of Electronic Protected Health Information (PHI)

1.1.  Printed material which includes PHI may be found in the following documents, labels or other printed media: customer encounter forms and labels, printouts from IS systems containing PHI, Magnolia Diagnostics notes, index cards or worksheets with customer’s information, photocopies of customer’s insurance cards, customer’s information on Post-It notes, personal reminders, emails, memos, telephone call logs, and other written communications that contain PHI. This list is not meant to be all inclusive.

1.2.  Documents that contain PHI which are subject to retention requirements, should be managed carefully to not expose PHI while in use, storage or transportation.

1.3.  Workforce Members are prohibited from destroying, altering, or discarding any information (with or without PHI) which may be subject to government investigations, audit, subpoenas, and search warrants. Standard document disposal policies and destruction procedures should be immediately suspended once there is notification that the documents are part of a government investigation, or a subpoena or search warrant has been served.

1.4.  Printed materials containing PHI that are not subject to retention requirements, must be destroyed or de-identified by an approved method. It is strictly prohibited to discard PHI into wastebaskets, recycling bins or other accessible locations or containers.

1.5.  Printed materials containing PHI that can be shredded or de-identified, must be kept in a locked container prior to transport and disposal.

1.6.  In the event that there is insufficient space or lockable containers available for storage prior to destruction or de-identification, the Laboratory Director or designee is to be contacted for a resolution, and the materials kept secure, until the issue is resolved.

RESOURCE: Special Publication 800-88, Revision 1, Guidelines for Media Sanitization has been approved as final as of December 17, 2014

Media sanitization refers to a process that renders access to target data on the media infeasible for a given level of effort. This guide will assist organizations and system owners in making practical sanitization decisions based on the categorization of confidentiality of their information.

2. De-Identification Standard and Methods

2.1.  Section 164.514(a) of the HIPAA Privacy Rule provides the standard for de-identification of protected health information. Under this standard, health information is not individually identifiable if it does not identify an individual and if the Magnolia Diagnostics has no reasonable basis to believe it can be used to identify an individual.

2.2.  Sections 164.514(b) and(c) of the Privacy Rule contain the implementation specifications that a covered entity must follow to meet the de-identification standard.

2.3.  The Privacy Rule provides two methods by which health information can be designated as de- identified which is Expert Determination and Safe Harbor.

2.4.  The Expert Determination method requires a person with appropriate knowledge of and experience with generally accepted statistical and scientific principles and methods for rendering information not individually identifiable: (i) Applying such principles and methods, determines that the risk is very small that the information could be used, alone or in combination with other reasonably available information, by an anticipated recipient to identify an individual who is a subject of the information; and (ii) Documents the methods and results of the analysis that justify such determination.

2.5.  The Safe Harbor Method requires that no parts or derivatives of any of the listed identifiers be disclosed in healthcare data. This method may be used by the Magnolia Diagnostics, through a third party, or a Workforce Member that has the expertise and equipment to complete this operation.

2.5.1.The Laboratory Director must pre-approve any Workforce Member or outside company that is utilized for de-identification.

2.6.  In general, examples of proper disposal methods may include, but are not limited to:

2.6.1.For PHI in paper records, shredding, burning, pulping, or pulverizing the records so that PHI is rendered essentially unreadable, indecipherable, and otherwise cannot be reconstructed.

2.6.2.Maintaining labeled prescription bottles and other PHI in opaque bags in a secure area and using a disposal vendor as a business associate to pick up and shred or otherwise destroy the PHI.

2.6.3.For PHI on electronic media, clearing (using software or hardware products to overwrite media with non-sensitive data), purging (degaussing or exposing the media to a strong magnetic field in order to disrupt the recorded magnetic domains), or destroying the media (disintegration, pulverization, melting, incinerating, or shredding).

3. Certificates of Destruction

3.1  All materials that contain PHI and are sent out to a contractor for disposal or de-identification, in bulk form, must be identified when destroyed with a Certificate of Destruction.

3.2  Internal methods for destroying or de-identification of material that contain PHI must be approved by the Laboratory Director.

4. Sanctions

4.1.  Workforce Members that do not follow policies for disposal of printed PHI are subject to disciplinary action, up to and including termination of employment or assignment.

4.2.  Business Associates found to be in violation of policies or laws regarding disposal or de- identification are subject to cancellation of service agreement and may be reported if found to be in violation of HIPAA laws to the appropriate authorities.

D-102 Disposal of Electronic Devices and Media

Introduction

The US National Institute of Standards and Technology describe several different methods can be used to sanitize media (making PHI that is stored in electronics irretrievable). Four of the most common are presented in this section. Users of this guide should categorize the information to be disposed of, assess the nature of the medium on which it is recorded, assess the risk to confidentiality, and determine the future plans for the media. The selected method should be assessed as to cost, environmental impact, etc., and a decision should be made that best mitigates the risks to an unauthorized disclosure of information.

Scope

All Magnolia Diagnostics Workforce Members shall be responsible for protecting PHI from unauthorized access, use, or disclosure. Except as authorized by the Laboratory Director, no interference with the storage of PHI or any hardware, software, or procedural mechanism that records or examines the activity of electronic PHI (“EPHI”) in Magnolia Diagnostics’ information system shall be permitted.

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director.

1. Disposal of Electronic Protected Health Information (PHI) Considerations

1.1.  Early in the system life cycle, a system is categorized using the guidance found in FIPS 199, NIST SP 800- 60 Rev. 1, or CNSSI 125318, including the security categorization for the system’s confidentiality. This security categorization is revisited at least every three years (or when significant change occurs within the system) and revalidated throughout the system’s life, and any necessary changes to the confidentiality category can be made. Once the security categorization is completed, the system owner can then design a sanitization process that will ensure adequate protection of the system’s information.

1.2.  A key decision on sanitization is whether the media are planned for reuse or recycle. Some forms of media are often reused to conserve an organization’s resources.

1.3.  While most devices support some form of Clear, not all devices have a reliable Purge mechanism. For moderate confidentiality data, the media owner may choose to accept the risk of applying Clear techniques to the media, acknowledging that some data may be able to be retrieved by someone with the time, knowledge, and skills to do so.

1.4.  If media are not intended for reuse either within or outside an organization due to damage or other reason, the simplest and most cost-effective method of control may be to destroy it.

2. Types of Disposal/Removal of PHI from Electronic Devices and Media

2.1. The sanitation method is used to sanitize media is to use software or hardware products to overwrite user addressable storage space on the media with non-sensitive data, using the standard read and write commands for the device. This process may include overwriting not only the logical storage location of a file(s) (e.g., file allocation table) but also should include all user addressable locations.

2.1.1. The security goal of the overwriting process is to replace Target Data with non-sensitive data. Overwriting cannot be used for media that are damaged or not rewriteable and may not address all areas of the device where sensitive data may be retained. The media type and size may also influence whether overwriting is a suitable sanitization method. For example, flash memory-based storage devices may contain spare cells and perform wear levelling, making it infeasible for a user to sanitize all previous data using this approach because the device may not support directly addressing all areas where sensitive data has been stored using the native read and write interface.

2.2 The Clear operation may vary contextually for media other than dedicated storage devices, where the device (such as a basic cell phone or a piece of office equipment) only provides the ability to return the device to factory state (typically by simply deleting the file pointers) and does not directly support the ability to rewrite or apply media-specific techniques to the non- volatile storage contents.

2.2.1 Where rewriting is not supported, manufacturer resets and procedures that do not include rewriting might be the only option to Clear the device and associated media. These still meet the definition for Clear as long as the device interface available to the user does not facilitate retrieval of the Cleared data.

2.3 Some methods of purging (which vary by media and must be applied with considerations described further throughout this document) include overwrite, block erase, and Cryptographic Erase, through the use of dedicated, standardized device sanitize commands that apply media- specific techniques to bypass the abstraction inherent in typical read and write commands. Destructive techniques also render the device Purged when effectively applied to the appropriate media type, including incineration, shredding, disintegrating, degaussing, and pulverizing. The common benefit across all these approaches is assurance that the data is infeasible to recover using state of the art laboratory techniques. However, Bending, Cutting, and the use of some emergency procedures (such as using a firearm to shoot a hole through a storage device) may only damage the media as portions of the media may remain undamaged and therefore accessible using advanced laboratory techniques.

1. Types of Disposal/Removal of PHI from Electronic Devices and Media, Continued.

3.1.  Degaussing renders a Legacy Magnetic Device Purged when the strength of the degausser is carefully matched to the media coercivity. The technique of Coercivity may be difficult to determine based only on information provided on the label. Therefore, refer to the device manufacturer for coercivity details. Degaussing should never be solely relied upon for flash memory-based storage devices or for magnetic storage devices that also contain non-volatile non-magnetic storage. Degaussing renders many types of devices unusable (and in those cases, Degaussing is also a Destruction technique).

3.2.  There are many different types, techniques, and procedures for media Destruction. While some techniques may render the Target Data infeasible to retrieve through the device interface and unable to be used for subsequent storage of data, the device is not considered Destroyed unless Target Data retrieval is infeasible using state of the art laboratory techniques. Disintegrate, Pulverize, Melt, and Incinerate. These sanitization methods are designed to completely Destroy the media. They are typically carried out at an outsourced metal Destruction or licensed incineration facility with the specific capabilities to perform these activities effectively, securely, and safely.

3.2.1.  Paper shredders can be used to Destroy flexible media such as diskettes once the media are physically removed from their outer containers. The shred size of the refuse should be small enough that there is reasonable assurance in proportion to the data confidentiality that the data cannot be reconstructed.

3.2.2.  To make reconstructing the data even more difficult, the shredded material can be mixed with non-sensitive material of the same type (e.g., shredded paper or shredded flexible media).

3.2.3.  The application of Destructive techniques may be the only option when the media fails and other Clear or Purge techniques cannot be effectively applied to the media, or when the verification of Clear or Purge methods fails (for known or unknown reasons).

1. Laboratory Director Responsibilities

4.1.  The Laboratory Director shall approve the method of destruction for each type of Electronic Devices and Media.

4.2.  The documentation of destruction shall be issued to the Laboratory Director and kept on record for a period of six (6) years.

5. Equipment Destruction Documentation

5.1. Following sanitization, a certificate of media disposition should be completed for each piece of electronic media that has been sanitized. A certification of media disposition may be a piece of paper or an electronic record of the action taken. For example, most modern hard drives include bar codes on the label for values such as model and serial numbers. The person performing the sanitization might simply enter the details into a tracking application and scan each bar code as the media is sanitized. Automatic documentation can be important as some systems make physical access to the media very difficult. When fully completed, the certificate should record at least the following details:

5.1.1.  Manufacturer, Model, Serial Number, Organizationally Assigned Media or Property Number (if applicable), Media Type (i.e., magnetic, flash memory, hybrid, etc.), Media Source (i.e., user or computer the media came from), Pre-Sanitization Confidentiality Categorization (optional), Sanitization Description (i.e., Clear, Purge, Destroy), Method Used (i.e., degauss, overwrite, block erase, crypto erase, etc.), Tool Used (including version), Verification Method (i.e., full, quick sampling, etc.), Post-Sanitization Confidentiality Categorization (optional), Post-Sanitization Destination (if known).

5.1.2.  For Sanitization and Verification; Position/Title of Person, Date, Location, Phone or Other Contact Information, and Signature

6. Sanctions

6.1. Workforce Members that do not follow policies for disposal of electronic devices or media containing PHI are subject to disciplinary action, up to and including termination of employment or assignment.

6.2. Business Associates found to be in violation of policies or laws regarding disposal electronic devices or media containing PHI are subject to cancellation of service agreement and may be reported if found to be in violation of HIPAA laws to the appropriate authorities.

Resource for a complete listing of destruction techniques as of 1/1/2017 – The National Institute of Standards and Technology (NIST), Guidelines for Media Sanitation, NIST Special Publication 800-88, Revision 1, December 2014.

<http://nvlpubs>.nist.gov/nistpubs/SpecialPublications/NIST.SP.800-88r1.pdf**.**

Section VI – Disaster Preparedness and Response

DI-100 Disaster Preparedness and the Community

Introduction

The U.S. Department of Health and Human Services (HHS), Office for Civil Rights (OCR), has published a bulletin to ensure that HIPAA covered entities and their business associates are aware of the ways in which patient information may be shared under the HIPAA Privacy Rule in an emergency situation, and to serve as a reminder that the protections of the Privacy Rule are not set aside during an emergency. The HIPAA Privacy Rule protects the privacy of patients’ health information (protected health information) but is balanced to ensure that appropriate uses and disclosures of the information still may be made when necessary to treat a patient, to protect the nation’s public health, and for other critical purposes.

Under the Privacy Rule, covered entities may disclose, without a patient’s authorization, protected health information about the patient as necessary to treat the patient or to treat a different patient. Treatment includes the coordination or management of health care and related services by one or more health care providers and others, consultation between providers, and the referral of patients for treatment. See 45 CFR §§ 164.502(a)(1)(ii), 164.506(c), and the definition of “treatment” at 164.501. For the purpose of this policy, treatment shall include the dispensing of pharmaceutical drugs and related supplies and equipment.

The HIPAA Privacy Rule recognizes the legitimate need for public health authorities and others responsible for ensuring public health and safety to have access to protected health information that is necessary to carry out their public health mission. Therefore, the Privacy Rule permits covered entities to disclose needed protected health information without individual authorization:

**To a public health authority, such as the Centers for Disease Control and Prevention (CDC) or a state or local health department, that is authorized by law to collect or receive such information for the purpose of preventing or controlling disease, injury or disability**. This would include, for example, the reporting of disease or injury; reporting vital events, such as births or deaths; and conducting public health surveillance, investigations, or interventions. A “public health authority” is an agency or authority of the United States government, a State, a territory, a political subdivision of a State or territory, or Indian tribe that is responsible for public health matters as part of its official mandate, as well as a person or entity acting under a grant of authority from, or under a contract with, a public health agency. See 45 CFR §§164.501 and 164.512(b)(1)(i). For example, a Medical Office may disclose to the CDC protected health information on an ongoing basis as needed to report all prior and prospective cases of patients exposed to or suspected or confirmed to have Ebola virus disease.

At the **direction of a public health authority**, to **a foreign government agency** that is acting in collaboration **with the public health authority** - 45 CFR 164.512(b)(1)(i).

To **persons at risk of contracting or spreading a disease or condition** if other law, such as state law, authorizes the Medical Office to notify such persons as necessary to prevent or control the spread of the disease or otherwise to carry out public health interventions or investigations - 45 CFR 164.512(b)(1)(iv).

Disclosures to Family, Friends, and Others Involved in an Individual’s Care and for Notification. **A Medical Office may share protected health information with a patient’s family members, relatives, friends, or other persons identified by the patient as involved in the patient’s care**. A Medical Office also may share information about a patient as necessary to identify, locate, and notify family members, guardians, or anyone else responsible for the patient’s care, of the patient’s location, general condition, or death. This may include, where necessary to notify family members and others, the police, the press, or the public at large. See 45 CFR 164.510(b).

The Medical Office **should get verbal permission from individuals or otherwise be able to reasonably infer that the patient does not object**, when possible; if the individual is incapacitated or not available, covered entities may share information for these purposes if, in their professional judgment, doing so is in the patient’s best interest.

In addition, a Medical Office may share protected health information with **disaster relief organizations** that, like the American Red Cross, are authorized by law or by their charters to assist in disaster relief efforts, for the purpose of coordinating the notification of family members or other persons involved in the patient’s care, of the patient’s location, general condition, or death. It is unnecessary to obtain a patient’s permission to share the information in this situation if doing so would interfere with the organization’s ability to respond to the emergency.

**Imminent Danger Health care providers** may share patient information with anyone as necessary to prevent or lessen a serious and imminent threat to the health and safety of a person or the public consistent with applicable law (such as state statutes, regulations, or case law) and the provider’s standards of ethical conduct - 45 CFR 164.512(j).

**Disclosures to the Media or Others Not Involved in the Care** of the Patient/Notification Upon request for information about a particular patient by name, a hospital or other health care facility may release limited facility directory information to acknowledge an individual is a patient at the facility and provide basic information about the patient’s condition in general terms (e.g., critical or stable, deceased, or treated and released) if the patient has not objected to or restricted the release of such information or, if the patient is incapacitated, if the disclosure is believed to be in the best interest of the patient and is consistent with any prior expressed preferences of the patient. See 45 CFR 164.510(a). In general, except in the limited circumstances described elsewhere in this Bulletin, affirmative reporting to the media or the public at large about an identifiable patient, or the disclosure to the public or media of specific information about treatment of an identifiable patient, such as specific tests, test results or details of a patient’s illness, may not be done without the patient’s written authorization (or the written authorization of a personal representative who is a person legally authorized to make health care decisions for the patient). See 45 CFR 164.508 for the requirements for a HIPAA authorization.

**Minimum Necessary for most disclosures**, a covered entity must make reasonable efforts to limit the information disclosed to that which is the “minimum necessary” to accomplish the purpose. (Minimum necessary requirements do not apply to disclosures to health care providers for treatment purposes.) Covered entities may rely on representations from a public health authority or other public official that the requested information is the minimum necessary for the purpose. For example, a covered entity may rely on representations from the CDC that the protected health information requested by the CDC about all patients exposed to or suspected or confirmed to have Ebola virus disease is the minimum necessary for the public health purpose. Internally, covered entities should continue to apply their role based access policies to limit access to protected health information to only those workforce members who need it to carry out their duties - 45 CFR §§ 164.502(b), 164.514(d).

**Business Associates** - A business associate of a covered entity (including a business associate that is a subcontractor) may make disclosures permitted by the Privacy Rule, such as to a public health authority, on behalf of a covered entity or another business associate to the extent authorized by its business associate agreement.

**Safeguarding Patient Information** - In an emergency situation, covered entities must continue to implement reasonable safeguards to protect patient information against intentional or unintentional impermissible uses and disclosures. Further, covered entities (and their business associates) must apply the administrative, physical, and technical safeguards of the HIPAA Security Rule to electronic protected health information.

**The HIPAA Privacy Rule is not suspended during a public health or other emergency**; however, the Secretary of HHS may waive certain provisions of the Privacy Rule under the Project Bioshield Act of 2004 (PL 108-276) and section 1135(b)(7) of the Social Security Act. If the President declares an emergency or disaster and the Secretary declares a public health emergency, the Secretary may waive sanctions and penalties against a covered hospital that does not comply with the following provisions of the HIPAA Privacy Rule: the requirements to obtain a patient's agreement to speak with family members or friends involved in the patient’s care - 45 CFR 164.510(b), the requirement to honor a request to opt out of the facility directory - 45 CFR 164.510(a), the requirement to distribute a notice of privacy practices - 45 CFR 164.520, the patient's right to request privacy restrictions - 45 CFR 164.522(a)the patient's right to request confidential communications. See 45 CFR 164.522(b).

**If the Secretary issues such a waiver**, it only applies: (1) in the emergency area and for the emergency period identified in the public health emergency declaration; (2) to hospitals that have instituted a disaster protocol; and (3) for up to 72 hours from the time the hospital implements its disaster protocol. When the Presidential or Secretarial declaration terminates, a hospital must then comply with all the requirements of the Privacy Rule for any patient still under its care, even if 72 hours has not elapsed since implementation of its disaster protocol.

**HIPAA Applies Only to Covered Entities and Business Associates** - The HIPAA Privacy Rule applies to disclosures made by employees, volunteers, and other members of a Medical Office’s or business associate’s workforce. Covered entities are health plans, health care clearinghouses, and those health care providers that conduct one or more covered health care transactions electronically, such as transmitting health care claims to a health plan. Business associates generally are persons or entities (other than members of the workforce of a covered entity) that perform functions or activities on behalf of, or provide certain services to, a covered entity that involve creating, receiving, maintaining, or transmitting protected health information. Business associates also include subcontractors that create, receive, maintain, or transmit protected health information on behalf of another business associate. The Privacy Rule does not apply to disclosures made by entities or other persons who are not covered entities or business associates (although such persons or entities are free to follow the standards on a voluntary basis if desired). There may be other state or federal rules that apply.

Scope

All Medical Office Workforce Members shall be responsible for protecting PHI from unauthorized access, use, or disclosure. Except as authorized by the Laboratory Director, no interference with the storage of PHI or any hardware, software, or procedural mechanism that records or examines the activity of electronic PHI (“EPHI”) in Medical Office’s information system shall be permitted.

This policy covers all Workforce Members, Business Associates, and all others that have access to or work with Protected Health Information (PHI) associated with Magnolia Diagnostics. In the event it is not clear if this policy applies to you, please contact the Laboratory Director.

1. Roles and Responsibilities

1.1. The Laboratory Director or designee shall take charge in the event of a disaster, only if qualified and properly trained in disaster preparedness.

1.1.1.In the event that the Laboratory Director lacks the qualification or the on-duty Manager is required to take on that role, the Laboratory Director shall remain as a resource to the store manager or whomever assumes the responsibility as the Disaster manager.

1.2. Workforce Members may take on non-traditional roles during a disaster. This may include such jobs as helping the Disaster Manager to the fullest extent possible, based on their ability and skills to provide such assistance.

Resource

The U.S. Department of Health and Human Services, Office for Civil Rights, BULLETIN: HIPAA Privacy in Emergency Situations, November 2014.

**QUICKCARD INFORMATION GUIDE 1.0 Civil and Criminal Penalties (HHS)**

Quick Information Guide 1.0: Civil and Criminal Penalties

(HIPAA) HITECH Act Enforcement Interim Final Rule

The Health Information Technology for Economic and Clinical Health (HITECH) Act, enacted as part of the American Recovery and Reinvestment Act of 2009, was signed into law on February 17, 2009, to promote the adoption and meaningful use of health information technology. Subtitle D of the HITECH Act addresses the privacy and security concerns associated with the electronic transmission of health information, in part, through several provisions that strengthen the civil and criminal enforcement of the HIPAA rules.

Section 13410(d) of the HITECH Act, which became effective on February 18, 2009, revised section 1176(a) of the Social Security Act (the Act) by establishing:

o Four categories of violations that reflect increasing levels of culpability;  
o Four corresponding tiers of penalty amounts that significantly increase the minimum penalty amount for each

violation; and  
o A maximum penalty amount of $1.5 million for all violations of an identical provision.

It also amended section 1176(b) of the Act by:

o Striking the previous bar on the imposition of penalties if the covered entity did not know and with the exercise of reasonable diligence would not have known of the violation (such violations are now punishable under the lowest tier of penalties); and Providing a prohibition on the imposition of penalties for any violation that is corrected within a 30-day time period, as long as the violation was not due to willful neglect.

The Enforcement Provisions are not found in the HHS Regulations, rather they are Congressionally promulgated statutes found in the U.S. Code:

42 U.S.C. §§ 1320d-5 & 1320d-6 & 42 U.S.C. § 1320d-5 Civil Violations. 42 U.S.C. § 1320d-6 Criminal Violations

General Penalty for Failure to Comply with Requirements and Standards U.S.C. § 1320d-5 (Civil Violations)

o Punishes any violation of regulations  
o Maximum penalty of $100 per violation  
o Cap of $25,000 per calendar year for each provision of the regulations that are violated

**QUICKCARD INFORMATION GUIDE 1.0 Civil and Criminal Penalties (HHS)**

Wrongful Disclosure of Individually Identifiable Health Information 42 U.S.C. § 1320D-6(a) (Criminal Violations)

Violation of federal law and violations must be committed “knowingly”. A person commits an act “knowingly” when it is done purposefully; that is, the act is a product of a conscious design, intent or plan

that it be done. *Horne v. State of Indiana, 445 N.E.2d 976 (1983)* The following are the categories of knowingly and in Violation:

o Knowingly and in violation of the regulations using or causing to be used a unique health identifier. o Knowingly and in violation of the regulations obtaining individually identifiable health information

relating to an individual.  
o Knowingly and in violation of the regulations disclosing individually identifiable health information to

another person.

Criminal Penalties for Violating § 1320d-6:

o Maximum penalties are set forth in §1320d-6(b) and actual sentencing is determined according to the Federal Sentencing Guidelines.

o Maximum Penalties (42 U.S.C. § 1320d-6(b)(1)) for any violation are a $50,000 fine, or one-year imprisonment, or both.

o Maximum Penalties (42 U.S.C. § 1320d-6(b)(2)) If offense is committed under false pretenses carry a $100,000 fine, or 5-years imprisonment, or both.

o Maximum Penalties (42 U.S.C. § 1320d-6(b)(3)) If the offense is committed with the intent to sell, transfer, or use individually identifiable health information for commercial advantage, personal gain, or malicious harm includes a $500,000 fine, or 10-years imprisonment, or both

Other US Statutes That Could Lead to Further Criminal or Civil Liability for Violating HIPAA

o Wire and Mail Fraud Statues, 18 U.S.C. §§ 1341 & 1343 o False Claims Act, 31 U.S.C. § 3729

If a Workforce Member becomes aware of intentional HIPAA violation(s) they are required to inform the Laboratory Director immediately or the Department of Health and Human Services (contact information located in Section G-100 Emergency Contact Information.

**QUICKCARD INFORMATION GUIDE 2.0 HIPAA State Security Laws Statutory References**

Quick Information Guide 2.0: HIPAA State Security Laws Statutory References

Select State HIPAA Security Laws

Please see state regulatory agencies for specific Guidelines

California

Cal. Penal Code § 471.5: *Alteration or Modification of Medical Record or Creation of False Medical Record with Fraudulent Intent*Cal. Civ. Code § 56.101: *Storage and Destruction of Records (Pharmaceutical Companies)*Cal. Civ. Code §56.36: *Violations of Patient Confidentiality of Medical Information*

Cal. Health & Safety Code § 1280.15 - *Reporting of Unlawful or Unauthorized Access or Disclosure of Patient Medical Information*

Florida/Georgia

Florida Statutes § 817.5681: *Protected Health Information Breaches* Georgia

Georgia Code Title 31 – Health *Chapter 33 – Health Records*

Massachusetts

105. Mass. Code Regs. 145.505: *Record Keeping Facilities and Equipment*105. Mass. Code Regs. 145.545: *Safeguards Against Loss and Use of Medical Records* 105. Mass. Code Regs. 145.555: *Release of Medical Record*

Michigan

Mich. Admin. Code r. 325.3848: *Medical Records Storage* Minnesota

MN ADC 9505.2197: *Vendor Responsibilities for Electronic Records* Missouri

Mo. Code Regs. Ann. tit. 13, § 70-3.160: *Electronic Submission of HealthNet Claims and Electronic Remittance*

New Hampshire

New Hampshire Code of Administrative Rules Ph §703.05: *Confidentiality under the Controlled Drug Act*

New Mexico

N.M. Stat. Ann. §24-14A-6: *Health Information System; Creation and Access*

N.M. Code R. §8.300.11.11B: *Confidentiality of Electronic Data*N.M. Stat. Ann. §24-14A-10: *Health Information System; Violation and Penalties*

**QUICKCARD INFORMATION GUIDE 2.0 HIPAA State Security Laws Statutory References**

New York

*New York Consolidated Laws, Public Health Law - PBH § 18.*

Ohio

Ohio Rev. Code Ann. § 3798.03 - *Duty of Covered Entities*

Oregon

Or. Admin. R. 325-015-0055 - *Protection of Patient Safety Data*Or. Rev. Stat. § 431.970 - *Reports to Health Professional Regulatory Boards (Pharmacist)* Or. Admin. R. 410-121- 4020 - *Information Access (Prescription Drug Monitoring)*

Pennsylvania

28 Pa. Code § 115.27: *Confidentiality of Medical Records* 28 Pa. Code § 563.1: *Patient Access to Medical Records* 28 Pa. Code § 115.23: *Preservation of Medical Records*

Texas

Texas Legislature House Bill 300 (H.B. 300)

Vermont

20-4 Vt. Code R. 1400:10.14: *Security of electronic equipment under the Board of Pharmacy*

Washington

Wash. Admin. Code § 246-455-080: *Security and Release of Reported Hospital Patient Discharge Data*Wash. Admin. Code § 246-875-070: *Confidentiality and Security of Pharmacy Patient Medication Record Systems Information*Wash. Rev. Code § 41.05.039: *Health Information Lead Organization and Secure Access* Wash. Rev. Code § 41.05.042: *Health Information Process Guidelines for Lead Organizations* Wash. Rev. Code § 69.41.055: *Electronic Communication of Prescription Information*Wash. Rev. Code § 70.02.150: *Healthcare Information Safeguards Provider Requirements*

Wisconsin

Wis. Stat. Ann. § 252.25 - *Violation of Law Relating to Health*

If a Workforce Member becomes aware of intentional HIPAA violation(s) they are required to inform the Laboratory Director immediately or the Department of Health and Human Services (contact information located in Section G-100 Emergency Contact Information.

**QUICKCARD INFORMATION GUIDE 3.0 HIPAA Definitions**

Quick Information Guide 3.0: HIPAA Definitions

Definitions

**Access** - The ability or the means necessary to read, write, modify, or communicate data or otherwise use any system that involves Protected Health Information.

**Auditable Event** - Any change to the security state of a system, any attempted or actual violation of the system access control or accountability security policies, or both (e.g., authentication attempts, access of health or financial records, information system start-up or shutdown, use of privileged accounts such as a system admin account).

**Authentication** – The corroboration that a person or entity is the one that it is claimed to be, which requires an individual identification parameter.

**Backup Data** - Retrievable, exact copy of data to be backed up, including applications, operating systems, database software, and other software supporting packages and tools, as well as the contents of databases and files.

**Breach** - The acquisition, access, use, or disclosure of protected health information in a manner not permitted under 45 CFR 164.402 which compromises the security or privacy of the protected health information. **Breach excludes - (i) any unintentional acquisition**, access, or use of protected health information by a workforce member or person acting under the authority of a covered entity (covered or support component) or a business associate, if such acquisition, access, or use was made in good faith and within the course and scope of authority and does not result in further access, use or disclosure in a manner not permitted under 45 CFR 164.402. **(ii) inadvertent disclosure** - by a person who is otherwise authorized to access protected health information at a covered entity (covered or support component) or business associate to another person authorized to access protected health information at the same covered entity (covered or support component) or business associate, or organized health care arrangement in which the covered entity (covered or support component) participates, and the information received as a result of such disclosure is not further accessed, used or disclosed in a manner not permitted under 45 CFR 164.402. **(iii) A disclosure of protected health information** - where a covered entity (covered or support component) or business associate has a good faith belief that an unauthorized person to whom the disclosure was made would not reasonably have been able to retain such information.

**(2) Except as provided in definition of “Breach”**, an acquisition, access, use, or disclosure of protected health information in a manner not permitted under 45 CFR 164.402 is presumed to be breach unless the covered entity (covered or support component) or business associate, as applicable, demonstrates that there is a low probability that the protected health information has been compromised based on a risk assessment of at least the following factors: **The nature and extent of the protected health information involved**, including the types of identifiers and the likelihood of re-identification. **The unauthorized person** who used the protected health information or to whom the disclosure was made **whether the protected health information** was actually acquired or viewed; and t**he extent to which the risk** to the protected health information has been mitigated.

**QUICKCARD INFORMATION GUIDE 3.0 HIPAA Definitions**

**Business Associate (BA)** - A person or organization that creates, receives, maintains, or transmits protected health information in any form or medium, including electronic media, in fulfilling certain functions or activities for a HIPAA- covered entity (covered or support component) and that performs a function or activity involving the use or disclosure of protected health information for or on behalf of the covered entity (covered or support component). A person or organization who only assists in the performance of the function or activity is also a business associate. This includes a person or organization that receives PHI from the covered entity (covered or support component), and one who obtains PHI for the covered entity (covered or support component). This includes, for example: data analysis, processing or administration; web site hosting; utilization review; quality assurance; billing; collections; benefit management; practice management; legal services; actuarial services; accounting and auditing; consulting; management and administrative services; accreditation; financial services; or any other service in which the person or organization obtains PHI from or for the covered entity (covered or support component). Members of the workforce are not considered business associates. The exchange of protected health information between providers of health care, for purposes of providing treatment to a patient, does not create a business associate relationship.

**Covered Entity -** Any entity that is a health care provider that conducts certain transactions in electronic form (called here a "covered health care provider"), a health care clearinghouse, or a health plan. A Medical Office is a “Covered Entity”.

**Digital Signature** - Cryptographic code that is attached to a piece of data. This code can be regularly verified to ensure that the data has not been improperly altered.

**Discovered Breach** - A breach is to be treated as discovered by a covered entity (covered or support component) or a business associate if any person, other than the individual committing the breach, which is an employee, officer or other agent of such entity or business associate knows or should reasonably have known of the breach. The time period for notification begins to run when the incident becomes known, not when it is determined that a breach as defined by the Rule has occurred.

**Electronic Health Record –** Protected Health Information is maintained in an electronic format.

**Electronic Media** - Electronic storage material on which data is or may be recorded electronically, including, for example, memory devices in computers (hard drives) and any removable/transportable digital memory medium, such as magnetic tape or disk, optical disk, or digital memory card, computers (i.e., servers, desktops, laptops), Storage Area Networks (SANS), floppy diskettes, backup tapes and cartridges; or transmission media used to exchange information already in electronic storage media. Transmission media include, for example, the Internet (wide-open), extranet (using Internet technology to link a business with information accessible only to collaborating parties), intranet, leased lines, dial-up lines, private networks, and the physical movement of removable/transportable electronic storage media.

**HIPAA Laboratory Director** - Individual entrusted with overall responsibility and management of data and information, including electronic data decision-making authority related to the development, implementation, and maintenance of policies and procedures related to University Data and may delegate responsibilities as they deem appropriate in specific functional areas

**HIPAA** - The Health Insurance Portability and Accountability Act of 1996, Public Law 104-191.

**QUICKCARD INFORMATION GUIDE 3.0 HIPAA Definitions**

**HIPAA Omnibus Rule** - The amendments to the HIPAA Security Regulations published in the Federal Register on January 25, 2013, entitled “Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification Rules under the Health Information Technology for Economic and Clinical Health Act and the Genetic Information Nondiscrimination Act; Other Modifications to the HIPAA Rules; Final Rule.”

**HIPAA Security Regulations -** Regulations published in the Federal Register by the Department of Health and Human Services on February 20, 2003 as the “Health Insurance Reform: Security Standards; Final Rule,” as amended or superseded from time to time. These include the Omnibus Rule amendments, published in the Federal Register on January 25, 2013.

**HITECH** - The Health Information Technology for Economic and Clinical Health Act, enacted under Title XIII of the American Recovery and Reinvestment Act of 2009, Public Law 111-5.

**Individual Identifiers** – Information collected that would uniquely identify an individual including; name, address, birth date, phone number, e-mail address, social security number, medical record number, account number, finger prints, photographic images, other unique identifier, license number, vehicle ID number or health insurance policy or member number.

**Information System** - Interconnected set of information resources under the same direct management control that shares common functionality. A system normally includes hardware, software, information, data, applications, communications, and people.

**Privacy Rule** – Provides patients and their authorized representatives, with few exceptions, the right to inspect, review, and receive a copy of medical records and billing records that are held by health plans and health care providers covered by the Privacy Rule.

**Protected Health Information** – Any individually identifiable health information that is a subset of health information, including demographic information collected from an individual, and any information in whatever form it exists, electronic, oral or otherwise, as defined in the Privacy Regulations (45 C.F.R. Section 160.103(i)) promulgated pursuant to HIPAA.

**Risk Analysis** - A systematic and analytical approach that identifies and assesses risks to the confidentiality, integrity or availability of a covered entity’s (covered or support component’s) EPHI. Risk analysis considers all relevant losses that would be expected if specific security measures protecting EPHI were not in place. Relevant losses include losses caused by unauthorized use and disclosure of EPHI and loss of data integrity.

**Workforce Member** - Employees, physicians, volunteers, trainees, and persons other than those deemed business associates whose conduct, in the performance of work for a covered entity (covered or support component), is under the direct control of such covered entity (covered or support component), whether or not they are paid by the covered entity (covered or support component), and who have access to PHI. This includes full and part time employees, volunteers, and third parties other than those deemed business associates who provide service to the covered entity (covered or support component).

**QUICKCARD INFORMATION GUIDE 4.0 Privacy Disclosure Guideline Examples (HHS)**

Quick Information Guide 4.0: Privacy Disclosure Guideline Examples

Questions and Answers from the U.S. Department of Health and Human Services

**Can health care providers engage in confidential conversations with other providers or with patients, even if there is a possibility that they could be overheard?**

Answer:

Yes. The HIPAA Privacy Rule is not intended to prohibit providers from talking to each other and to their patients. Provisions of this Rule requiring Covered Entities to implement reasonable safeguards that reflect their particular circumstances and exempting treatment disclosures from certain requirements are intended to ensure that providers’ primary consideration is the appropriate treatment of their patients. The Privacy Rule recognizes that oral communications often must occur freely and quickly in treatment settings. Thus, covered entities are free to engage in communications as required for quick, effective, and high-quality health care. The Privacy Rule also recognizes that overheard communications in these settings may be unavoidable and allows for these incidental disclosures.

For example, the following practices are permissible under the Privacy Rule, if reasonable precautions are taken to minimize the chance of incidental disclosures to others who may be nearby:

* Health care staff may orally coordinate services at hospital nursing stations.
* Nurses or other health care professionals may discuss a patient’s condition over the phone with the patient, a

provider, or a family member.

* A health care professional may discuss lab test results with a patient or other provider in a joint treatment area.
* A physician may discuss a patients’ condition or treatment regimen in the patient’s semi-private room.
* Health care professionals may discuss a patient’s condition during training rounds in an academic or training institution.
* A pharmacist may discuss a prescription with a patient over the pharmacy counter, or with a physician or the patient over the phone.

In these circumstances, reasonable precautions could include using lowered voices or talking apart from others when sharing protected health information. However, in an emergency situation, in a loud emergency room, or where a patient is hearing impaired, such precautions may not be practicable. Covered entities are free to engage in communications as required for quick, effective, and high-quality health care.

**QUICKCARD INFORMATION GUIDE 4.0 Privacy Disclosure Guideline Examples (HHS)**

**Does the HIPAA Privacy Rule permit a doctor to discuss a patient’s health status, treatment, or payment arrangements with the patient’s family and friends?**

Answer:

Yes. The HIPAA Privacy Rule at 45 CFR 164.510(b) specifically permits covered entities to share information that is directly relevant to the involvement of a spouse, family members, friends, or other persons identified by a patient, in the patient’s care or payment for health care. If the patient is present, or is otherwise available prior to the disclosure, and has the capacity to make health care decisions, the covered entity may discuss this information with the family and these other persons if the patient agrees or, when given the opportunity, does not object. The covered entity may also share relevant information with the family and these other persons if it can reasonably infer, based on professional judgment, that the patient does not object. Under these circumstances, for example:

* A doctor may give information about a patient’s mobility limitations to a friend driving the patient home from the hospital.
* A hospital may discuss a patient’s payment options with her adult daughter.
* A doctor may instruct a patient’s roommate about proper medicine dosage when she comes to pick up her friend

from the hospital.

* A physician may discuss a patient’s treatment with the patient in the presence of a friend when the patient brings the friend to a medical appointment and asks if the friend can come into the treatment room.

Even when the patient is not present or it is impracticable because of emergency circumstances or the patient’s incapacity for the covered entity to ask the patient about discussing her care or payment with a family member or other person, a covered entity may share this information with the person when, in exercising professional judgment, it determines that doing so would be in the best interest of the patient. See 45 CFR 164.510(b). Thus, for example:

* A surgeon may, if consistent with such professional judgment, inform a patient’s spouse, who accompanied her husband to the emergency room, that the patient has suffered a heart attack and provide periodic updates on the patient’s progress and prognosis.
* A doctor may, if consistent with such professional judgment, discuss an incapacitated patient’s condition with a family member over the phone.

In addition, the Privacy Rule expressly permits a covered entity to use professional judgment and experience with common practice to make reasonable inferences about the patient’s best interests in allowing another person to act on behalf of the patient to pick up a filled prescription, medical supplies, X-rays, or other similar forms of protected health information. For example, when a person comes to a pharmacy requesting to pick up a prescription on behalf of an individual he identifies by name, a pharmacist, based on professional judgment and experience with common practice, may allow the person to do so.

**QUICKCARD INFORMATION GUIDE 4.0 Privacy Disclosure Guideline Examples (HHS)**

**Does the HIPAA Privacy Rule permit a doctor to discuss a patient’s health status, treatment, or payment arrangements with a person who is not married to the patient or is otherwise not recognized as a relative of the patient under applicable law (e.g., state law)?**

Yes. The HIPAA Privacy Rule at 45 CFR 164.510(b) permits covered entities to share with an individual’s family member, other relative, close personal friend, or any other person identified by the individual, the information directly relevant to the involvement of that person in the patient’s care or payment for health care. In addition, HIPAA allows a covered entity to disclose information about a patient as necessary to notify, or assist in the notification of (including by helping to identify or locate), such a person of the patient’s location, general condition, or death. In either circumstance, the person can be a patient’s family member, relative, guardian, caregiver, friend, spouse, or partner. The Privacy Rule defers to a covered entity’s professional judgment in these cases and does not require the entity to verify that a person is a family member, friend, or otherwise involved in the patient’s care or payment for care.

HIPAA permits a covered entity to share PHI with anyone from the list of potential recipients, subject to the conditions included at 45 CFR 164.510(b) and described below. Moreover, the list of potential recipients of PHI under 45 CFR 164.510(b) is in no way limited or impacted by the sex or gender identity of either the patient or the potential recipient.

When making disclosures to the persons listed under 45 CFR 164.510(b), a covered entity should get verbal permission from the patient when possible, or otherwise be able to reasonably infer that the patient does not object to the disclosure, before disclosing information to these persons. If the patient is incapacitated or not available, a covered entity may share information when, in its professional judgment, doing so is in the patient’s best interest. Finally, if the individual is deceased, a covered entity may share information with a person who was involved in the individual's care or payment for care prior to the individual's death, unless doing so is inconsistent with any prior expressed preference of the individual that is known to the covered entity.

In contrast to the permitted disclosures described above, there are circumstances in which a covered entity is required to disclose information to a family member or other person involved in an individual’s care. Specifically, in some cases, a spouse, partner, or other person involved in a patient’s care will be the patient’s personal representative and thus generally have the authority to exercise the patient’s rights under the HIPAA Privacy Rule on the patient’s behalf, such as the right to access medical and other health records as provided at 45 CFR 164.524(a). A covered entity must treat all personal representatives as the individual for purposes of the Privacy Rule, in accordance with 45 CFR 164.502(g). This means a covered entity may not deny a personal representative, as defined in 45 CFR 164.502(g), the rights afforded to the personal representative under 45 CFR 164.502(g) of the Privacy Rule for any reason, including because of the sex or gender identity of the personal representative. For example, if a state grants legally married spouses health care decision making authority for each other, such that legally married spouses are personal representatives under 45 CFR 164.502(g), the legally married spouse is the patient’s personal representative and a covered entity must provide the spouse access to the patient’s records. In this example, a covered entity that does not provide a patient’s lawful spouse with access because of the sex of the spouses would be in violation of the Privacy Rule. Similarly, if a person has been granted a legal health care power of attorney for an individual that grants the person the authority to make health care decisions for the individual in a state, that person satisfies the definition of personal representative and a covered entity in that state that denies the person personal representative status because of the gender identity of the person would be in violation of the Privacy Rule.

For more information about HIPAA and Marriage, see http://www.hhs.gov/hipaa/for-professionals/special- topics/same-sex-marriage/index.html”. More general information about when HIPAA permits disclosures to family members, friends, and others involved in a patient’s care or payment for care is available at http://www.hhs.gov/hipaa/for-individuals/family-members-friends/index.html (for individuals) and at http://www.hhs.gov/sites/default/files/provider\_ffg.pdf -PDF

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Laboratory Director Date